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Mutation or inactivation of RB occurs in most human tumors and results in the 
deregulation of several E2F family transcription factors.  Among the E2F family, E2F3 
has been implicated as a key regulator of cell proliferation and E2f3 gene amplification 
and overexpression is detected in some human tumors.  To study the role of E2F3a in 
tumor development, we established a transgenic mouse model expressing E2F3a in a 
number of epithelial tissues via a keratin 5 (K5) promoter.  Transgenic expression of 
E2F3a leads to hyperproliferation, hyperplasia and increased levels of p53-independent 
apoptosis in transgenic epidermis.  Consistent with data from human cancers, the E2f3a 
transgene is found to have a weak oncogenic activity on its own and to enhance the 
response to a skin carcinogenesis protocol. While E2F3a induces apoptosis in the absence 
of p53, the inactivation of both p53 and p73, but not p73 alone, significantly impairs 
apoptosis induced by E2F3a. This suggests that both p53 and p73 contribute to E2F3a 
induced apoptosis but that their function is compensatory.  Even though data suggest that 
E2F3a carries out its unique apoptotic activity in part through another E2F family 
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member E2F1, unlike E2F1, the ARF tumor suppressor is required for E2F3a-induced 
apoptosis.  While both E2F3a and E2F1 require ATM for apoptosis, E2F3a activates 
ATM through a distinct mechanism from E2F1.  The overexpression of E2F3a results in 
the accumulation of DNA damage in K5 transgenic keratinocytes and normal human 
fibroblasts (NHFs).  In response to this, the DNA damage checkpoint kinase ATM is 
activated, and phosphorylation of the downstream targets p53 and the histone variant 
H2AX are significantly increased. Additional studies show that increased Cdk activity 
and aberrant DNA replication contributes to DNA damage, ATM activation and 
apoptosis in response to deregulated E2F3a, which suggest that aberrant replication 
imposed by deregulated E2F3a plays an important role in the activation of the ATM 
DNA damage response pathway.  Activation of ATM by E2F3a is not affected by loss of 
ARF or E2F1. Meanwhile, E2F3a-induced ARF upregulation is not affected by E2F1 
loss.  The above results indicate that E2F3a engages several parallel pathways involving 
E2F1, ARF and the ATM kinase, and these pathways cooperate to promote apoptosis.  
 
 viii 
Table of Contents 
List of Tables......................................................................................................xi 
List of Figures....................................................................................................xii 
Chapter I  Introduction.........................................................................................1 
1.1 E2F Family ...........................................................................................1 
1.1.1    The history of E2F ..................................................................1 
1.1.2    Members of the E2F family.....................................................2 
1.2 E2F and cell cycle control .....................................................................5 
1.2.1    The cell cycle in mammalian cells...........................................5 
1.2.2    The roles of E2F in cell cycle..................................................7 
1.2.3    Activator E2Fs trigger S phase entry. ......................................9 
1.3 E2F and apoptosis ............................................................................... 10 
1.3.1    Activator E2Fs induce apoptosis ........................................... 10 
1.3.2    Apoptosis pathways by E2F .................................................. 12 
1.4 ATM and the DNA damage response .................................................. 15 
1.4.1    Oncogene induce DNA damage and the DNA damage response15 
1.4.2    The DNA damage response signaling pathways .................... 17 
1.5 The link between E2F and cancer ........................................................ 19 
1.5.1    Rb/E2F pathway and cancer.................................................. 19 
1.6 Skin  carcinogenesis model.................................................................. 22 
1.6.1    Skin keratinocytes undergo constant proliferation and 
differentiation. ......................................................................... 22 
1.6.2    Skin carcinogenesis is a multistage process. .......................... 25 
Chapter II Materials and Methods ...................................................................... 29 
2.1 Generation of K5 E2F3a transgenic mouse lines. ................................. 29 
2.2 BrdU incorporation.............................................................................. 29 
2.3 Activated caspase 3 immunohistochemistry......................................... 30 
 ix 
2.4 Two-stage mouse skin carcinogenesis study. ....................................... 30 
2.5 Real-time quantitive PCR. ................................................................... 31 
2.6 Cells and viruses. ................................................................................ 32 
2.6.1    Mouse embryo fibroblasts (MEF) isolation and culture ......... 32 
2.6.2    Primary human fibroblasts .................................................... 33 
2.6.3    Adenoviral infections............................................................ 33 
2.7 Western blot analysis........................................................................... 33 
2.8 Caspase-3 activity assay. ..................................................................... 34 
2.9 γH2AX immunofluorescence............................................................... 35 
2.10 Immunohistochemical staining for p53 phospho-serine 15................. 35 
2.11 Single-cell gel electrophoresis (comet) assay. .................................... 36 
Chapter III Deregulated E2F3a induces proliferation, tumorigenesis and p53-
independent apoptosis in vivo .................................................................... 38 
3.1 Rationale and significance................................................................... 38 
3.2 Results ................................................................................................ 40 
3.2.1    Generation of K5 E2F3a transgenic mice .............................. 40 
3.2.2    Overexpression of E2F3a increases both proliferation and 
apoptosis.................................................................................. 43 
3.2.3    K5 E2F3a transgenic mice have increased tumor development in 
both two stage and spontaneous tumor assay............................ 46 
3.3 Discussion........................................................................................... 52 
Chapter IV Characterizing E2F3a apoptotic pathways........................................ 55 
4.1 Rationale and significance................................................................... 55 
4.2 Results ................................................................................................ 57 
4.2.1    Overexpression of E2F3a induces markers of DNA double-strand 
breaks in vivo........................................................................... 57 
4.2.2    Deregulated expression of E2F3a causes DNA damage......... 62 
4.2.3    E2F3a-induced apoptosis is dependent on ATM in K5 E2F3a 
transgenic mice and in human cell cultures. ............................. 64 
4.2.4    Replication inhibition reduces E2F3a induced DNA damage and 
ATM mediated apoptosis ......................................................... 67 
 x 
4.2.5    E2F3a activates ATM independent of E2F1 or p19ARF. .......... 70 
4.2.6    E2F3a induced apoptosis requires either p53 or p73.............. 82 
4.3 Discussion........................................................................................... 83 
Chapter V Concluding remarks.......................................................................... 88 
5.1 Summary and discusion of the studies ................................................. 88 
5.2 Future directions.................................................................................. 93 
References ......................................................................................................... 95 
Vita …............................................................................................................. 111 
 xi 
List of Tables 
Table 1 Spontaneous K5-positive tumors in K5 E2F3a mice .............................. 49 
Table 2 Comparison of K5 E2F Transgenic models ........................................... 90 
 xii 
List of Figures 
 
Figure 1. The E2F family of transcription factors. ................................................3 
Figure 2.  Role of activator E2Fs in cell cycle progression. ..................................8 
Figure 3.  E2F mediated apoptosis pathways. ..................................................... 13 
Figure 4. DNA damage response pathways. ....................................................... 18 
Figure 5.  Activation of E2F by disturbances of the p16INK4a-cyclin D-retinoblastoma 
tumor suppressor pathway in cancer. ............................................. 20 
Figure 6.  The structure of human skin. .............................................................. 23 
Figure 7.  Multistage model of skin carcinogenesis. ........................................... 27 
Figure 8.  Development of K5 E2F3a transgenic mouse lines. ............................ 41 
Figure 9. Expression of E2F target genes in K5 E2F3a transgenic mice. ............ 42 
Figure 10.  Hyperplasia and hyperproliferation in K5 E2F3a transgenic epidermis.44 
Figure 11. E2F3a-induced p53-independent apoptosis in transgenic epidermis... 45 
Figure 12.  Spontaneous tumor development in K5 E2F3a transgenic mice. ....... 47 
Figure 13.  Histological appearance of tumors from K5 E2F3a transgenic mice. 48 
Figure 14.  K5 E2F3a transgenic mice have an enhanced response to two-stage skin 
carcinogenesis. .............................................................................. 50 
Figure 15.  Deregulated E2F3a induces DNA damage marker γH2AX foci formation 
in vivo............................................................................................ 58 
Figure 16.  Overexpression of E2F3a activates ATM in K5 E2F3a transgenic mice 
and in human cell cultures. ............................................................ 59 
Figure 17.  Deregulated E2F3a induces DNA damage in primary keratinocytes and 
human cell cultures as measured by the comet assay...................... 63 
 xiii 
Figure 18.  Inactivation of Atm reduces apoptosis in K5 E2F3a transgenic mice and 
human cell cultures........................................................................ 65 
Figure 19.  DNA replication inhibitor Aphidicolin reduces E2F3a-induced DNA 
damage. ......................................................................................... 68 
Figure 20.  Overexpression of Cdk inhibitor p21 reduces E2F3a-induced DNA 
damage and response. .................................................................... 69 
Figure 21.  Overexpression of E2F3a upregulates endogenous E2F1 protein level.71 
Figure 22.  E2F3a induces E2F1-dependent apoptosis in vivo and in vitro.......... 72 
Figure 23.  E2F3a activates ATM independent of E2F1. .................................... 74 
Figure 24. Inactivation of Arf reduces apoptosis in vivo and in vitro................... 75 
Figure 25.  E2F3a activates ATM independent of ARF. ..................................... 79 
Figure 26.  Expression of p19ARF increases in K5 E2F3a transgenic epidermis with 
wild type or E2f1 null background. ................................................ 80 
Figure 27.  Loss of both p53 and p73 impairs E2F3a-induced apoptosis. ............ 81 
Figure 28.  Schematic model of E2F3a-induced apoptosis pathways. ................. 84 
 1 
Chapter I  Introduction 
 
1.1 E2F FAMILY  
1.1.1    The history of E2F 
E2Fs were originally identified by their ability to bind to and activate the 
adenoviral E2 gene promoter and were named the E2 binding factor (Kovesdi et al., 
1986). E2 gene activation by E2F requires the function of adenoviral early region 1A 
(E1A) transforming protein (Bagchi et al., 1990).  The retinoblastoma protein (RB) 
binding domain of E1A is critical for E1A to mediate E2 gene activation by E2F.  This 
led to the finding that in normal cells, E2F is inhibited by its association with RB. E1A 
stimulates cell cycle entry by sequestering RB and inducing the release of E2F (Bagchi et 
al., 1991; Bandara and La Thangue, 1991; Nevins, 1992).  E1A and several other viral 
proteins including the large T antigen of SV40 and the E7 oncoprotein of human 
papilloma virus all bind to RB and release E2F activity (Dyson et al., 1989; Whyte et al., 
1988). E2F controls the transcription of a group of genes that are important for cell cycle 
progression (Dyson, 1998). The critical role E2F plays in cell cycle control is highlighted 
by the requirement of E1A to bind RB in order to induce DNA synthesis and to 
contribute to oncogenic transformation. 
E2F also associates with and is regulated by two other members of the RB family, 
p107 and p130 (Ewen et al., 1991; Li et al., 1993).   These proteins belong to the same 
multigene family and differ in their abilities to interact with different E2F family 
members.  This will be further addressed in the next section.   
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Around the same time when E2F was discovered, a group identified 
differentiation regulated transcription factor 1 (DRTF1).  This factor was down regulated 
during the differentiation of F9 embryonic carcinoma stem cells (La Thangue and Rigby, 
1987).  The consensus DNA-binding site of DRTF1 was found to be the same as that of 
E2F, and DRTF1 also interacted with RB (Bandara and La Thangue, 1991; La Thangue 
and Rigby, 1987).  Now it is clear that DRTF1 and E2F are the same factor. Importantly, 
during the purification and microsequencing process of DRTF1, a key component of 
DRTF1/E2F was discovered and called DRTF protein 1 (DP1) (Girling et al., 1993) 
(Figure 1).  DP1 is a heterodimerization partner for members of the E2F family.  
Although related factors (known as DP2/3 and DP4) can also heterodimerize with E2F, 
DP1 appears to be the major component of cellular E2F activity (Bandara et al., 1994; 
Milton et al., 2006; Wu et al., 1995).  
 
1.1.2    Members of the E2F family 
The E2F family of transcription factors are critical regulators of cellular 
proliferation, differentiation, development and apoptosis.   A number of E2F family 
members have been identified, including six E2F (E2F1-6) and three DP (DP1, DP2/3 
and DP4) proteins (DeGregori and Johnson, 2006; Dyson, 1998; Helin, 1998; Milton et 
al., 2006).   Recently two new E2F members E2F7 and E2F8 have been reported (de 
Bruin et al., 2003; Maiti et al., 2005b) (Figure 1). The six distinct genes, E2F1 through 
E2F6 of the E2F family encode structurally related proteins with highly conserved DNA-
binding and dimerization domains.  E2F1-6 bind DP proteins to form functional 
heterodimers, which bind with high affinity to E2F DNA-binding sites in target gene 




Figure 1. The E2F family of transcription factors.   
This figure summarizes the structural characteristics of E2Fs.  Shown are the domains 
found in the E2F/DP family members including the cyclin A binding domain; NLS, 
nuclear localization signal; DNA binding domain; LZ, leucine zipper together with MB, 
marked box domain mediates dimerization with DP; and transactivation domain which 







DP proteins and instead may bind DNA as monomers.  With the exception of E2F6-8, the 
carboxy terminus of each E2F protein contains the defined transcriptional activation 
domain.  Embedded within the transactivation domain is a region of homology involved 
in binding to proteins of the RB tumor suppressor family. 
Adding additional complexity to the E2F family, the E2F3 gene encodes two 
protein products (E2F3a and E2F3b) through the use of alternative promoters at one 
genomic locus (He et al., 2000; Leone et al., 2000). E2F3a is expressed in proliferating 
cells with peak expression at the G1/S phase boundary while E2F3b, which lacks amino-
terminal sequences found in E2F3a, is expressed constitutively, including in quiescent 
cells.  
The E2Fs have been divided into several subclasses according to their 
transcriptional regulatory properties on E2F target genes.  One subclass includes E2F1, 
E2F2 and E2F3a, which are referred to as the activator E2Fs because they 
transcriptionally activate E2F target genes such as thymidine kinase and cyclin E.  The 
activator E2Fs associate predominately with RB and their expression is cell cycle 
regulated with maximum expression in late G1 phase (Lees et al., 1993). This control is 
the result of several mechanisms, with one being E2F-dependent transcriptional 
repression in quiescent cells (Adams et al., 2000; Johnson et al., 1994b; Sears et al., 
1997).  A second mechanism of regulation is interaction with cyclin A-Cdk2 through the 
amino terminus cyclin A binding domain and consequent phosphorylation by the cyclin 
A-Cdk2 complex, which results in decreased DNA binding activity of the E2F-DP dimer 
(Dynlacht et al., 1997; Kitagawa et al., 1995; Krek et al., 1994).  E2F is also subject to 
ubiquitin mediated protein degradation, though this mechanism is not limited to activator 
E2Fs, and the association with RB protects E2F from proteolysis (Campanero and 
Flemington, 1997; Hateboer et al., 1996; Hofmann et al., 1996).  Another subclass of 
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E2Fs, which includes E2F3b, E2F4 and E2F5, are referred to as repressor E2Fs because 
their primary function appears to be to repress the transcription of E2F target genes when 
in association with RB, p107, or p130. This subclass is expressed constitutively but 
transcriptional repression by these factors primarily occurs in quiescent and early G1 
cells.  E2F4 and E2F5 nuclear localization appears to depend on association with RB and 
DP family members (Lindeman et al., 1997; Magae et al., 1996; Muller et al., 1997). 
E2F4 is predominantly nuclear in quiescent and early G1 cells, translocating to the 
cytoplasm during progression into S phase.  The third subclass, which includes E2F6, 7 
and E2F8 also appear to function as transcriptional repressors of E2F target genes but do 
so independent of the RB family (de Bruin et al., 2003; Maiti et al., 2005a; Morkel et al., 
1997).  
 
1.2 E2F AND CELL CYCLE CONTROL 
1.2.1    The cell cycle in mammalian cells 
The cell division cycle is usually divided into four distinct phases, G1 (gap 1), S 
(synthesis), G2 (gap2) and M (mitosis) phases (Sherr and Roberts, 1999). Gap phases 
allow cells time to grow and double their mass of proteins and organelles in order to 
replicate their DNA and divide.  DNA duplication occurs during S phase, which requires 
10-12 hours and occupies about half of the cell cycle time in most mammalian cells.  
After S phase, chromosome segregation and cell division occur in M phase, which 
requires less than an hour in most mammalian cells.  
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Growth factors exert their effect during the G1 phase.  The restriction (R) point 
defines a critical time in late G1 after which a cell is committed to DNA replication even 
if the extracellular signals that stimulate cell growth and division are removed.  After the 
R point, cell cycle progression can only be halted at checkpoints by conditions of cellular 
stress, such as mitotic-spindle defects or DNA damage.  
Cyclin-dependent kinases (Cdks) lie at the heart of the cell cycle control system. 
Many enzymes and proteins control cyclical changes in Cdk activity. Among them, the 
most important Cdk regulators are cyclins, which undergo a cycle of synthesis and 
degradation in each cell cycle.  Cyclical changes in cyclin levels result in the cyclic 
assembly and activation of the cyclin-Cdk complexes; this activation in turn triggers cell-
cycle events.  Cyclin binding leads to partial activation of Cdk by exposing the active site 
of Cdk.  Cdk-activating kinase (CAK) will then phosphorylate near the Cdk active site 
resulting in full activation of cyclin-Cdk kinases.   The rise and fall of cyclin levels is the 
primary determinant of Cdk activity during the cell cycle.  However, to fine tune Cdk 
activity at specific stages of the cell cycle, phosphorylation by Wee1 protein kinase 
inhibits Cdk activity and dephosphorylation by Cdc25 increases Cdk activity.  The 
association and dissociation of Cdk inhibitor proteins (CKIs) can also regulate the 
activity of cyclin-Cdk complexes.  
The sequential activation of Cdk4/6, Cdk2, and Cdc2 (Cdk1) controls the orderly 
progression of cell cycle through the four phases.  In G1 phase after growth factor 
stimulation, increased cyclin D synthesis occurs and newly synthesized cyclin D 
assembles with Cdk4/6 into active Cdk4/6-cyclin D complexes.  By contrast, the 
expression of cyclin E is triggered by internal signaling pathways.  In the cases of the 
ordered activation of the remaining cyclin-Cdk complexes, each cyclin-Cdk complex 
triggers the activation of the next cyclin-Cdk species and also induces its own 
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destruction.  Under conditions of cellular stress, cell cycle progression is disrupted by the 
activation of checkpoint pathways that ultimately lead to the inhibition of one or more 
cyclin-Cdk complexes.   
 
1.2.2    The roles of E2F in cell cycle 
The E2F transcription factors regulate a number of the genes that encode products 
required for cells to progress into S phase from quiescence.  These genes encode cell 
cycle regulators such as cyclin E, cyclin A, cyclin B, Cdc2, Cdc25A and RB; enzymes 
that are involved in nucleotide biosynthesis such as dihydrofolate reductase (DHFR), 
thymidylate synthetase and thymidine kinase (TK); and the main components of the 
DNA-replication machinery, including Cdc6, ORC1 and the minichromosome 
maintenance (Mcm) proteins (Ishida et al., 2001; Muller et al., 2001; Wang et al., 1999).  
   The transcriptional activity of E2F1-5 is regulated through association with the 
RB (retinoblastoma) tumor suppressor protein or the related RB family proteins, p107 
and p130 (Dyson, 1998; Helin, 1998). When bound to E2F, RB family members not only 
block transcriptional activation by E2F-DP heterodimers, but can also actively repress 
transcription by recruiting histone deacetylases (HDAC) and other chromatin remodeling 
factors to the promoters of E2F-responsive genes (Brehm et al., 1998; Dyson, 1998).   
Formation of RB family proteins/E2F complexes is cell cycle regulated.  When quiescent 
cells are stimulated to enter the cell cycle, cyclin D expressed at the G1-phase of the cell 
cycle activate their associated Cdk4/6, which phosphorylate the RB family proteins 
(Sherr, 1996; Weinberg, 1995) along with cyclin E-Cdk2 complexes during progression 
of the cell cycle, resulting in sequential dissociation of HDAC/Rb/E2F complexes.  This 
leads to derepression as well as activation of E2F–regulated genes. Furthermore, free 
E2Fs have the ability to interact with histone acetyltransgerases (HATs), such as p/CAF 
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Figure 2.  Role of activator E2Fs in cell cycle progression.    
Hypophosphorylated RB binds to E2F in early-G1 phase and inhibits its activity. The 
E2F/DP1/RB complex also actively suppresses the transcription of E2F target genes by 
recruiting chromatin remodeling enzymes, including histone deacetylases (HDACs).  
When cells progress to mid-G1 phase, RB is sequentially phosphorylated by cyclin 
D/Cdk4,6 and cyclin E/Cdk2 and hyperphosphorylated RB releases E2F/DP dimer, which 
initiates transcription of the genes required for G1/S transition.  In this step, E2F interacts 
with p300/CBP or p/CAF to recruit histone acetylase activity to the target promoter and 







or p300/CBP which act as co-activators to promote transcription at the target promoters 
(Martinez-Balbas et al., 2000; Marzio et al., 2000). These events result in an ensuing S 
phase entry (Figure 2). 
1.2.3    Activator E2Fs trigger S phase entry. 
E2F1, E2F2, and E2F3a are potent transcriptional activators of E2F-responsive 
genes (Dynlacht et al., 1997; Helin et al., 1992). It is a well established that the activator 
E2Fs are important in regulating gene expression at the G1/S phase transition of the 
mammalian cell cycle (Botz et al., 1996; Dyson, 1998; Leone et al., 1998) and are 
important for cell cycle progression (Bagchi et al., 1990; Lavia and Jansen-Durr, 1999). 
When overexpressed, all these activator E2Fs have the ability to induce quiescent cells to 
enter S phase and positively regulate cell proliferation. In some contexts, E2F4 and 5 also 
can induce S phase when overexpressed (DeGregori et al., 1997; Johnson et al., 1993; 
Lukas et al., 1996; Vigo et al., 1999).  Ectopic expression of E2F1 can also override 
various growth arrest signals, including TGF-β, DNA damage and the Cdk inhibitors 
p16, p21, p27 (DeGregori et al., 1997; Mann and Jones, 1996; Schwarz et al., 1995).   
Moreover, overexpressed E2F1, E2F2 and E2F3a can induce transformation of an 
established cell line (Singh et al., 1994; Xu et al., 1995), or transform primary rat embryo 
cells in cooperation with other oncogenes such as an activated Ras oncogene (Johnson et 
al., 1994a).  More importantly, transgenically expressed E2F1 and E2F3a can induce 
tumor development in mouse models (Paulson et al., 2006; Pierce et al., 1998a; Pierce et 
al., 1999).   
Endogenous activator E2Fs also have been shown to play important roles in the 
control of cellular proliferation. The combined loss of all activator E2Fs is sufficient to 
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completely block cellular proliferation (Wu et al., 2001), which indicates that the 
activator E2Fs have overlapping roles in the induction of cell cycle entry, and 
subsequently cell proliferation.  In agreement with these results, inhibition of endogenous 
E2F3 by microinjection of anti-E2F3 antibodies causes cell cycle arrest in primary cells 
(Leone et al., 1998)  E2f3-deficient mouse embryonic fibroblasts (MEFs) have a reduced 
rate of proliferation in both primary and transformed cells caused by defective activation 
of almost all known E2F responsive genes in response to mitogen stimulation (Humbert 
et al., 2000). Furthermore, in these E2F3 null mouse models, E2F3 loss has a stronger 
negative effect on cell proliferation compared with the loss of E2F1 and E2F2 (Humbert 
et al., 2000; Leone et al., 1998). Therefore, E2F3a is considered to be a strong positive 
regulator for cell proliferation. It was also shown that following mitogenic induction in 
primary fibroblasts, E2F3a activates most known E2F-responsive genes whose products 
are rate limiting in DNA replication such as Cdc6 and the Mcm proteins (Hateboer et al., 
1998; Kowalik et al., 1998). Thus, E2F3a is a crucial factor that determines the rate of 
proliferation in primary fibroblasts (Humbert et al., 2000).  
 
1.3 E2F AND APOPTOSIS 
1.3.1    Activator E2Fs induce apoptosis 
            In addition to inducing proliferation, deregulated E2F activity triggers apoptosis 
in mammalian cells and transgenic mouse systems. Ectopic expression of Drosophila 
E2F (dE2F) in flies also induces apoptosis (Asano et al., 1996; Du et al., 1996).  
Concerning the function of E2F in apoptosis induction, some consider it a specific 
function of E2F1, while others disagree.  Early findings show that when overexpressed in 
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REF52 fibroblasts, the apoptotic induction function is unique to E2F1 (DeGregori et al., 
1997; Hallstrom and Nevins, 2003).  Supporting data show that ectopic expression of 
E2F1 leads to apoptosis in cultured cells (Kowalik et al., 1995; Shan and Lee, 1994; Wu 
and Levine, 1994) and transgenic mice (Holmberg et al., 1998; Pierce et al., 1998a; 
Pierce et al., 1999; Shan and Lee, 1994). Further studies have shown that inactivation of 
RB in mouse brain epithelium induces aberrant proliferation and apoptosis that are 
suppressed by E2F1 deficiency (Pan et al., 1998).  
            Conversely, other experiments using either overexpression systems or loss of 
function systems suggest other activator E2Fs trigger cells undergo apoptosis as well. 
The ectopic expression of estrogen receptor (ER) regulated fusions with E2F1, E2F2 or 
E2F3 all induce apoptosis in Rat1 fibroblasts (Vigo et al., 1999).  A report shows that the 
E2F1 marked box domain has a unique proapoptotic activity among E2Fs (Hallstrom and 
Nevins, 2003).  On the other hand, our unpublished results show that introduction of a 
mutation in the marked box domain of E2F3a significantly reduces the level of apoptosis 
induced by overexpression of E2F3a.  Also, E2F1 or E2F3 deficiency, but not E2F2 
deficiency, can rescue the inappropriate apoptosis observed in several tissues in mouse 
embryos with inactivated RB (Saavedra et al., 2002; Tsai et al., 1998; Ziebold et al., 
2001). These findings indicate that deregulated E2F3 and possibly E2F2 induce apoptosis 
and E2F3 also plays a role in apoptosis that occurs in the absence of RB. While ectopic 
expression of E2F3 was reported to induce apoptosis in some experimental cell systems 
(Vigo et al., 1999) but not in others (DeGregori et al., 1997; Kowalik et al., 1998), our 
recent results together with others from different transgenic mice systems show 
overexpression of E2F3 induces apoptosis in vivo (Lazzerini Denchi and Helin, 2005; 
Paulson et al., 2006; Vigo et al., 1999). These systems provide more reliable results that 
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E2F3 does induce apoptosis, since the animal system provides a more physiologically 
relevant environment and largely avoids the variations in different cell culture systems. 
 
1.3.2    Apoptosis pathways by E2F 
The mechanisms underlying E2F-induced apoptosis are quite complex, but can be 
classified as either p53-dependent (Kowalik et al., 1995; Shan and Lee, 1994) or p53-
independent pathways (Hsieh et al., 1997; Irwin et al., 2000).  In p53-dependent 
apoptosis, one mechanism underlying the accumulation of p53 induced by deregulated 
E2F1 expression is the direct transactivation of the p19Arf tumor suppressor gene (p14Arf 
in human) by E2F1 (Bates et al., 1998; Palmero et al., 1998).  ARF interacts and 
sequesters Mdm2 E3 ubiquitin ligase to nucleoli (Pomerantz et al., 1998; Weber et al., 
1999; Zhang and Xiong, 1999) and blocks nucleo-cytoplasmic shuttling of Mdm2 (Tao 
and Levine, 1999; Zhang and Xiong, 1999), resulting in the inhibition of Mdm2’s 
function.  By inhibiting Mdm2, ARF inhibits the ability of Mdm2 to target p53 for 
ubiquitination and subsequent degradation (Weber et al., 1999). Thus, E2F1 induced 
increase in ARF levels leads to dissociation of Mdm2 from p53 and results in p53 
stabilization. The level of p53 is normally maintained at low levels because Mdm2 is a 
transcriptional target of p53 and thus participates in a negative feedback loop.  However, 
several reports demonstrate that deregulated E2F1 induces apoptosis in a p53-dependent 
but ARF-independent manner (Russell et al., 2002; Tsai et al., 2002).  In the absence of 
ARF, E2F1-induced apoptosis is correlated with p53 phosphorylation by the ATM kinase 




Figure 3.  E2F mediated apoptosis pathways. 
In the classical model, E2F1 upregulates the transcription of the Arf tumor suppressor 
gene, which interferes with Mdm2 mediated p53 degradation and results in increased p53 
level.  Activation of p53 leads to the transcription of its downstream targets such as p21 
for cell cycle arrest and proapoptotic factors bax, Noxa, Puma and other genes that 
promote apoptosis.  More recent findings provide evidence that ATM is responsible for 
E2F-induced apoptosis. The deregulation of E2F1 in some way activates ATM and 
causes it to phosphorylate a series of downstream effectors including Chk2 and p53, 
leading to p53 stabilization and activation and consequently apoptosis.   In p53-
independent apoptosis, E2F1 upregulates the activity of the p53 homologue p73, which 
activates p53 responsive genes to promote apoptosis.  Overexpression of E2F1 also 
upregulates proapoptotic factors such as Bak, Bad and Bid, effector caspases including 
caspase 3 and 7, and Apaf-1, which activates caspase 9 and eventually activates effector 
caspase 3 and 6. 
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activates ATM is under extensive study. 
Besides p53-dependent apoptosis introduced above, E2F1 also induces p53-
independent apoptosis. The p53 homologue p73 is believed to be directly activated by 
E2F1, leading to activation of p53 responsive genes and apoptosis (Irwin et al., 2000; 
Stiewe and Putzer, 2000).  Also DNA microarray studies show that ectopic expression of 
E2Fs up-regulate expression of proapoptotic members of the Bcl-2 family, such as Bok, 
Bad, Bak and Bid1, and effector caspases, including caspase-3 and caspase-7 (Ma et al., 
2002; Muller et al., 2001).  Induction of E2F1 activity also results in an increase of 
mRNA and protein levels of Apaf1, which activates caspase-9 and consequently caspase-
3 and caspase-6 (Moroni et al., 2001).  ARF can also function as a tumor suppressor 
independently of p53 (Weber et al., 2000), by inducing apoptosis through Bax (Suzuki et 
al., 2003), or by inhibiting the processing of rRNA (Sugimoto et al., 2003).  As well, 
ATM has recently been shown to phosphorylate proapoptotic Bcl-2 family member Bid 
in response to DNA damage, suggesting a possible mechanism for ATM- induced p53-
independent apoptosis (Kamer et al., 2005; Zinkel et al., 2005). 
While the activities of E2Fs are regulated by posttranslational control through 
protein-protein interactions, they are also subject to transcriptional control.  This 
transcriptional control is partially regulated by one or more E2F family members.  It has 
been shown that E2F3 induces E2F1 expression by binding and activating its promoter 
(Araki et al., 2003; Neuman et al., 1994; Wells et al., 2000).  The ability of E2Fs to 
regulate each other provides one explanation for the phenomenon that the E2F 
transcription factors have their specific roles in cell proliferation, apoptosis, 
differentiation and development, yet share some redundant functions.  Recently, it was 
shown that increased apoptosis mediated by deregulated E2F3 is dependent on 
endogenous E2F1 (Denchi et al., 2005).  Since E2F family members inter-regulate each 
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other, and overexpression of E2F3 upregulates the mRNA level of E2F1, it would be 
interesting to know how depriving endogenous E2F1 will affect E2F3a-induced apoptosis 
in our transgenic mouse model.  
 
1.4 ATM AND THE DNA DAMAGE RESPONSE 
1.4.1    Oncogene induce DNA damage and the DNA damage response 
Recent reports show that in several types of human tumors, the ATM DNA 
damage response pathway is activated.  In carcinomas of the lung and breast, there is 
constitutive activation of Chk2 (DiTullio et al., 2002), an effector kinase that is activated 
by ATM (Ataxia Teleangiectasia Mutated) in response to DNA double-strand breaks 
(DSBs).   The early precursor lesions of human urinary bladder, breast, lung and colon 
tumors and experimentally induced skin hyperplasia with overexpression of growth 
factors all express DNA damage response markers. These include phosphorylated kinases 
ATM and Chk2, phosphorylated histone H2AX and p53, p53 accumulation and 
formation of 53BP1 foci (Bartkova et al., 2005; Gorgoulis et al., 2005).  Apoptosis is also 
observed in these precursor lesions. Three more recent studies report that oncogene-
induced senescence is also mediated by the DNA damage checkpoint pathway (Bartkova 
et al., 2006; Di Micco et al., 2006; Mallette et al., 2007).  During the complicated process 
of tumor development, many factors contribute to the formation of cancer. To determine 
the factors that evoke the DNA damage response observed in the above cancerous 
lesions, studies have shown that oncogenes such as E2F1 and Myc cause DNA damage in 
cultured cells (Lindstrom and Wiman, 2003; Vafa et al., 2002).  Furthermore, a series of 
studies have also demonstrated in cell culture experiments that a number of oncogenes 
such as cyclin E, Cdc25A, E2F1 and Myc, when overexpressed, induce the 
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phosphorylation of several DNA damage checkpoint markers.  These include serine 15 
phosphorylated p53, γH2AX, serine 966 phosphorylated SMC1 and Threonine 68 
phosphorylated Chk2 (Bartkova et al., 2005; Bartkova et al., 2006; Gorgoulis et al., 2005; 
Powers et al., 2004; Rogoff et al., 2004).    
It has been proposed that activation of the ATM signaling pathway by oncogene-
induced damage mediates tumorigenesis barriers that slow or inhibit the progression of 
preneoplastic lesions to neoplasia. One such barrier is apoptosis or cell cycle arrest 
(Bartkova et al., 2005; Gorgoulis et al., 2005), while a second barrier is oncogene-
induced senescence (Bartkova et al., 2006; Mallette et al., 2007).  Cells with an intact 
DNA damage response frequently arrest or die in response to DNA damage, thus 
reducing the likelihood of progression to malignancy.  Mutations in apoptosis, DNA-
damage responses or in mitotic-checkpoint pathways, can permit the survival or the 
continued growth of cells with genomic abnormalities, thereby enhancing the chance of 
malignant transformation.   Senescence was initially identified as a response of tissue 
culture cells to eroded telomeres or activated oncogenes (Lowe et al., 2004). The 
relevance of senescence to human cancer was unclear until its recent demonstration in 
preneoplasia (Collado et al., 2005; Michaloglou et al., 2005).  Oncogene-induced 
senescence has been associated with increased expression of the tumor suppressors 
p16INK4A and ARF (Lowe et al., 2004; Narita et al., 2003; Serrano et al., 1997).  Recent 
studies have shown that activation of the DNA damage checkpoint pathway is critical in 
mediating oncogene-induced senescence (Bartkova et al., 2006; Mallette et al., 2007).  
Taken together, data from human cancer tissue and from cell culture studies suggest that 
deregulated oncogenes have the ability to induce DNA damage relatively early in cancer 
development and activate DNA damage responses that result in halted cell cycle 
progression, programmed cell death or senescence. 
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1.4.2    The DNA damage response signaling pathways 
            In response to DNA damage, the activation of PI(3)K (phosphatidyl-inositol-3 
kinase)-like kinases (PIKKs) such as ATM (ataxia telangiectasia mutated) and ATR 
(ATM- and Rad3- related) are one of the first steps characterized to date in the activation 
of DNA damage checkpoint pathways. ATM primarily responds to DNA breaks while 
ATR plays a critical role in the response to cellular stress that inhibits replication fork 
progression. Because many types of DNA damage result both in the direct damage of the 
DNA and the arrest of DNA replication forks, ATM and ATR participate together in 
many cellular stress responses.  Here we emphasize the role of ATM in response to DNA 
double-strand breaks (DSBs).  ATM is a serine/threonine kinase with a 350 kilodalton 
molecular weight.  ATM is not essential for critical cellular functions such as cell cycle 
progression or cellular differentiation, because humans, mice or cells that lack ATM are 
viable (Shiloh and Kastan, 2001).  ATM kinase is mostly activated when cells are under 
stresses that affect DNA or chromatin structure.  DNA-double strand breaks are 
recognized by sensors as the Mre11-Rad50-Nbs1 (MRN) complex, which then recruits 
ATM to sites of damage.  In normal cells, ATM exists as a homodimer in which the 
kinase domain is physically blocked.  The introduction of double-strand breaks (DSB) 
lead to a conformational change in ATM, which induces intermolecular 
autophosphorylation on serine 1981.  The phosphorylation of ATM on serine 1981 causes 
dissociation of the homodimer and results in activated monomeric ATM (Bakkenist and 
Kastan, 2003). Activated ATM phosphorylates histone H2AX on its C-terminus (termed 
γH2AX) and also phosphorylates other mediator proteins such as 53BP1, MDC1, 





Figure 4. DNA damage response pathways.  
At the site of DNA double-strand breaks (DSB), before the activation of the response 
network, DSB sensors, including MRE11, RAD50, and NBS1 that form MRN 
complexes, are rapidly recruited to the site of damage.  The sensors convey a damage 
signal to transducers, for example ATM and ATR, which in turn phosphorylate the C-
terminus of histone H2AX at serine 139 and elicit coordinated recruitment and 
phosphorylation of mediators to the DNA damage site. The mediators enhance and 
amplify the signal of transducer kinases and cause the phosphorylation of numerous 





facilitates ATM kinase to phoshorylate downstream target effectors such as Chk2, p53 
and SMC1. The above series of processes lead to the biological outcomes of the 
checkpoint responses including cell cycle arrest, apoptosis, and DNA damage repair 
(Figure 4).    
 
1.5 THE LINK BETWEEN E2F AND CANCER 
1.5.1    Rb/E2F pathway and cancer 
While RB interacts with many proteins, the critical targets of RB cell cycle 
repressive activity are the E2F transcription factors (Morris and Dyson, 2001; Nevins, 
2001).  Even though E2Fs are rarely mutated in human tumors, there is much evidence to 
suggest that the activation of E2F transcription factors, via perturbation of the p16INK4a-
cyclin D/Cdk4,6-RB tumor suppressor pathway, is a key event in the development of 
most cancers (Figure 5).  RB was the first tumor suppressor to be identified and its loss of 
function is found in the majority of all human tumors (Weinberg, 1992).  In 
untransformed cells, without mitogenic factor stimulation, RB binds to E2F and inhibits 
E2F responsive genes, and consequently prevents the initiation of DNA replication and 
cell cycle progression.   When there is Rb loss of function, E2F will be released to 
activate E2F responsive genes and induce S phase entry and cell proliferation.  The 
RB/E2F pathway is regulated directly by cyclin D-Cdk4/6 and indirectly by the p16INK4a 
Cdk inhibitor.  The second most common mutation that happens in human cancers is p16 
mutation.  The p16 protein inhibits cyclin D-Cdk4 activity, and in the absence of p16, 
increased Cdk activity leads to RB phosphorylation and E2F accumulation. Thus, loss of 
p16 activity is functionally equivalent to RB loss of function.   Activating mutations in 
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Figure 5.  Activation of E2F by disturbances of the p16INK4a-cyclin D-retinoblastoma 
tumor suppressor pathway in cancer. 
The retinoblastoma tumor suppressor, RB is inactivated in many human tumors.  At the 
same time, almost all RB positive tumors carry either activating mutations in the cyclin D 
or Cdk4 genes or inactivating mutations in the Cdk4 inhibitor, p16INK4a.  The inactivation 
of RB can occur through roughly three mechanisms: loss or mutation of the Rb gene,  
inactivation by the binding of oncoproteins of DNA tumor viruses,  or the deregulated 
phosphorylation of RB mediated by the aberrant activation of cyclin D or Cdk4 or the 






the cyclin D  or  Cdk  genes  can  also  occur  in  cancer and leads to increased activity of 
cyclin D-Cdk4 activity, increased phosphorylation of RB and release of E2F. 
            E2Fs not only transactivate cell cycle-related genes but also repress gene 
expression.  Furthermore, E2Fs are important in regulating both cell proliferation and 
antiproliferative processes such as apoptosis and senescence. How E2F3a’s cell 
proliferative function and apoptosis induction function are balanced and affect the 
outcome of tumor development is of great interest.  In a mouse  model  with Rb-deficient 
tumors, E2F3 loss results in suppression of pituitary tumors but promotes the 
development and metastasis of medullary thyroid carcinomas (Ziebold et al., 2003).  This 
suggests that E2F3 acts as either an oncogene or a tumor suppressor in different Rb 
mutant tumors.  Several studies have shown increased E2F3a gene amplification and 
increased expression in human cancers, including transitional cell carcinoma of the 
bladder, prostate cancers and retinoblastoma (Feber et al., 2004; Foster et al., 2004; 
Oeggerli et al., 2004).  Also, E2F3a is used as a marker for large-cell lung cancer but not 
for other types of lung cancers (Borczuk et al., 2003).  Previous studies in mice have 
shown that the E2F transcription factors have different effects in tumor development 
(Pierce et al., 1999; Wang et al., 2000). To determine what roles E2F3a plays in 
tumorigenesis, we will use a K5 E2F3a transgenic mice model to study if E2F3a induces 
tumor development with and without carcinogenic pressures. 
    When RB is hypophosphorylated, it binds to the activator E2Fs (E2F1, 2, 3a), 
and negatively regulates their function of promoting cell cycle progression from G1 to S 
phase.  Thus, loss of functional RB leads to inappropriate release of the activating E2Fs, 
and increased expression of E2F-regulated genes.  Using an overexpression system to 
study E2F3a imitates the physiological condition of RB loss of function. One of the 
approaches to study individual E2F target specificity is to use overexpression systems to 
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monitor the transcription of E2F responsive genes and correlated phenotypes.  E2F 
transcription factors appear to play contrasting roles in proliferation and apoptosis, tumor 
suppression and oncogenesis, with each E2F family member having distinct and partially 
redundant functions.  Here we use in vitro and in vivo overexpression systems to imitate 
the loss of RB function in physiological systems to explore the specific roles and 
mechanisms E2F3a plays in cell proliferation, apoptosis and tumorigenesis. 
 
1.6 SKIN  CARCINOGENESIS MODEL 
1.6.1    Skin keratinocytes undergo constant proliferation and differentiation. 
            The skin is composed of two major compartments that are separated by a 
basement membrane.  The compartment under the basement membrane is called the 
dermis, a dense connective tissue layer that plays a supportive role in skin function. The 
compartment lying above the basement membrane is called the epidermis.  The epidermis 
consists of several layers of keratinocytes: the innermost basal layer to the outermost 
stratum corneum (Figure 6).  The keratinocyte is the predominant cell type in the skin 
epidermis.  The function of keratinocytes includes formation of a mechanical barrier, 
defense against pathogens and other noxious agents from the outside, and preventing 
water loss.  
           One of the important features of epidermis is its self-renewing nature.  This 
depends on constant proliferation of cells in the basal layer to produce new keratinocytes 
and their differentiation and outward migration.  A careful analysis of the growth 




Figure 6.  The structure of human skin.   
The skin is composed of epidermis and dermis. The two sections are separated by a 
basement membrane. The dermis is a dense connective tissue layer that plays a 
supportive role in skin function.  The epidermis consists of several layers of 
keratinocytes, from the innermost basal layer to the outermost stratum corneum. The 
basal layer contains proliferating keratinocytes and the corneal layer contains mostly 
differentiated, dead cells.  The skin also contains appendages such as hair follicles, 
sebaceous glands and sweat glands.  The skin stem cells reside in the bulge region of the 







size of the clones they are capable of generating in a single plating: holoclones, 
meroclones and paraclones (Barrandon and Green, 1987).  Holoclones, which have the 
greatest proliferative potential, contain cells that almost all go on to form proliferative 
colonies on passaging.  It is tempting to speculate that the holocone generating cells in 
vitro might be keratinocyte stem cells in vivo which provide the virtually unlimited 
proliferative capability of skin keratinocytes.  Making use of the  slow cycling nature of 
stem cells, researchers have been able to locate keratinocyte stem cells (label-retaining 
cells) in the mouse skin.  The majority of them reside in the bulge region of the hair 
follicle (just below the sebaceous gland), with a small fraction in the basal layer of 
interfollicular epidermis (Cotsarelis et al., 1990; Morris and Potten, 1994).  It is believed 
that the stem cells in the bulge region are multipotent and those in the basal layer of 
interfollicular epidermis are progeny, or unipotent progeny of multipotent bulge cells 
(Alonso and Fuchs, 2003).  
            The regulation of keratinocyte proliferation is an extremely complex process. It 
depends on the availability of growth factors, degree of cell differentiation, and cell 
attachment to the substrate. Abnormalities of keratinocyte proliferation are of pathogenic 
significance in many skin disorders.  Overexpression of growth factors such as epidermal 
growth factor (EGF) family members and IGF-1 may be common mechanisms shifting 
skin keratinocyte into pathological proliferative pathways.  Under inflammatory 
conditions, the interleukins seem to play an important role in activating the pathological 
pathway of keratinocyte proliferation.  In vitro, some interleukins are equally potent as 
EGF in stimulating keratinocyte proliferation (Gniadecki, 1997). 12-O-
tetradecanoylphorbol-13-acetate (TPA) treatment or UV irradiation also causes 
keratinocyte proliferation.  Curiously, the bulge cells require repeated treatment with 
TPA to induce proliferation, where as basal layer stem cells are more easily induced to 
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divide (Morris and Potten, 1999), suggesting that the basal layer stem cells are important 
in the initial skin response to outside stimuli.   
When the population of basal cells expands as a result of constant cellular 
proliferation, some cells detach from the basement membrane and begin to move outward 
toward the skin surface.  These cells are eventually sloughed from the skin surface after 
undergoing terminal differentiation, a process that shares some similarities with apoptosis 
(Gandarillas, 2000).  Although this process remains poorly understood at the molecular 
levels, much knowledge has been obtained from in vitro models of keratinocyte 
differentiation.  It is well known that incubation of cultured keratinocytes with high 
concentrations of calcium (above 0.1 mM) leads to keratinocyte differentiation.  It is 
believed that calcium activates the G-protein-coupled calcium-sensing receptor and leads 
to the activation of phospholipase C, which in turn produces two important second 
messengers diacylglycerol and inositol triphosphate (IP3) (Bikle et al., 2001).  IP3 
stimulates the release of calcium from intracellular stores, resulting in increased 
intracellular free calcium concentrations (Cai).  The increase in diacylglycerol and Cai 
activate several isoforms of protein kinase C.  Protein kinase C in turn activates the AP-1 
family of transcription factors, which regulate the expression of the genes that are 
involved in keratinocyte differentiation (Bikle et al., 2001).   
 
1.6.2    Skin carcinogenesis is a multistage process. 
The mouse skin model of carcinogenesis has been instrumental in developing 
many concepts currently applied to human neoplasias, including the idea that cancer 
develops through a multistep process that involves many genetic alterations (Bikle et al., 
2001; Conti, 1994; DiGiovanni, 1992; Yuspa, 1998). It is often referred to as the “two-
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stage” skin carcinogenesis model, but it actually consists of three mechanistic stages 
termed initiation, promotion, and progression (Figure 7) (DiGiovanni, 1992).    
Initiation is generally carried out by application of a single dose of a carcinogen to 
the dorsal mouse skin.  In most carcinogenesis protocols, the initiation step utilizes a 
chemical agent 7,12-dimethylbenz[a]anthracene (DMBA) or physical agents such 
ultraviolet (UV) and ionizing radiation (IR).  These agents usually cause permanent 
genetic changes such as mutations, deletions or translocations in a critical gene.  Not all 
cells in the animal exposed to initiating agents would be initiated even if all cells incurred 
DNA damage and mutation.  An initiated cell has to have proliferative potential and 
cannot have the normal potential to terminally differentiate.  The most frequent genetic 
change in the DMBA-initiated mouse skin is a mutation at codon 61 of the H-ras 
oncogene, which cause it to be constitutively active (Balmain and Brown, 1988; 
Quintanilla et al., 1986).  In most cases, the initiated cells gain a growth advantage 
compared to normal cells.   
Initiation alone, however, is not sufficient for the development of visible tumors 
during the lifespan of the animal.  The selective clonal expansion of the initiated cells in 
the promotion stage occurs as a result of exposure of the initiated skin to repetitive 
treatments with an irritating, non-mutagenic agent such as 12-O-tetradecanoyl-phorbol-
13-acetate (TPA).  Tumor promotion involves prolonged and repeated application of 
promoter agents and producing biochemical and cellular responses typical of gene 
deregulation.  For example, the activation of protein kindase C, EGF receptor, ErbB2 and 
c-Src occurs in response to TPA treatment in mouse epidermis and ODC, c-Fos and c-
Myc expression are increased (Conti, 1994; DiGiovanni, 1994; Yuspa, 1998).  The 
endpoint of the promotion stage is the formation of squamous papillomas, which are 
exophytic, noninvasive lesions. Papillomas in early development (in the first ten weeks)  
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Figure 7.  Multistage model of skin carcinogenesis.   
Cancer development involves a multistep process.  This model provide an example and 
consists of three stages.  Initiation involves a single dose of a known carcinogen such as 
DMBA applied to the dorsal skin, which causes a specific genetic change in a critical 
gene. In the promotion stage, the selective clonal expansion of initiated cells is achieved 
by repeated exposure of the initiated skin to a non-genotoxic agent such as TPA. 
Progression is characterized by the conversion of a subset of benign tumors into 
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will regress without continued treatment with the promoter but in later stages, the 
development of papillomas become independent of the promoting agent.  Upregulation of 
cyclin D1 and E2F factors, along with other cell cycle regulators correlates with promoter 
independence in these later stages (Rodriguez-Puebla et al., 1998; Zhang et al., 1997). 
Progression is characterized by the conversion of benign papillomas into 
malignant squamous cell carcinomas with phenotypes of rapid growth, invasiveness and 
angiogenesis.  Genomic instability, ras gene amplification and p53 mutations are 
common during progression (Yuspa, 1998).  The conversion process occurs 
spontaneously without the need of continuous tumor promoter application.   
In this dissertation, I will first characterize the role of deregulated E2F3a in tumor 
development.  To determine this, a K5 E2F3a transgenic mouse model will be developed 
and subject to different tumor studies.  A spontaneous tumor study is a useful assay to 
determine the oncogenic property of E2F3a.  Further study in two-stage skin 
carcinogenesis assay will help characterize the effect of deregulated E2F3a on tumor 
development in response to chemical carcinogen.  I will also determine if E2F3a has an 
apoptotic activity in vivo, and if so, I will further determine the pathways by which 










Chapter II Materials and Methods 
2.1 GENERATION OF K5 E2F3A TRANSGENIC MOUSE LINES.   
The K5 E2F3a transgene was constructed by inserting a 1.6 kb cDNA fragment 
encoding full-length human E2f3a into the SnaBI site of pBS-KS-BK5 plasmid, which 
contains the bovine K5 promoter, the rabbit β-globin intron 2, and the simian virus 40 
polyadenylation signal (Ramirez et al., 1994).  Founder transgenic mice were made by 
microinjecting the purified transgene into the pronuclei of zygotes and then implanting 
the zygotes into pseudo-pregnant female mice. Lines were established and maintained by 
backcrossing the founders to the FVB strain.   
K5 E2F3a transgenic mice (line E2F3.5) in the FVB background were bred to 
mice containing an inactivated Atm allele to generate K5 E2F3a mice heterozygous for 
Atm.  F1 transgenic mice heterozygous for Atm were then crossed to Atm heterozygous 
mice to generate K5 E2F3a transgenic and non-transgenic siblings that were either wild 
type, heterozygous, or nullizygous for Atm. The same procedures were used to generate 
K5 E2F3a transgenic and non-transgenic mice that were either wild type, heterozygous, 
or nullizygous for Arf or E2f1. After 6 weeks of age, sibling mice were sacrificed and 
skin sections were collected for analysis.  
 
2.2 BRDU INCORPORATION.   
Mice at 6-8 weeks of age were injected introperitoneally with 170ul of 20mM 
bromodeoxyuridine (BrdU) and allowed to incorporate it for 20 minutes before being 
sacrificed. Lower dorsal skin samples were fixed in formalin, paraffin embedded, and 
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sectioned. Immunohistochemistry staining was performed with an antibody to BrdU 
(Becton Dickinson) at 1:500 dilutions. Interfollicular basal layer keratinocytes were 
examined microscopically to determine the percentage of BrdU incorporation by 
calculating the ratio of stained and unstained cells.  At least 1000 cells were counted.  
 
2.3 ACTIVATED CASPASE 3 IMMUNOHISTOCHEMISTRY.   
Skin sections were fixed in formalin, paraffin embedded and sectioned. After 
deparaffinization and hydration, sections were incubated with antibody specific for the 
activated form of caspase-3 (R&D Systems, Inc.) at 1:2000 dilutions for 30 minutes. 
Then the slides were washed and incubated with secondary anti-rabbit antibody and 
enzyme conjugated using the Histostatin-plus kit (Zymed) for 10 minutes each. Slides 
were then stained with the kit’s diaminobenzidine mixture, rinsed and counterstained 
with hemotoxylin for 12 to 15 seconds. Apoptosis level were determined by observing 
the stained slides microscopically and calculated as the average number of activated 
caspase-3 positive cells per 10 mm of interfollicular epidermis. 
 
2.4 TWO-STAGE MOUSE SKIN CARCINOGENESIS STUDY.   
The dorsal skin of 6 to 8 week-old lines K5 E2F3.2 and E2F3.5 transgenic mice 
and wild type sibling controls were shaved 1 to 2 days before initiation. Mice were 
initiated with 10nM DMBA in 200 ul of acetone by applying topically to the shaved 
dorsal skin. Mice were promoted twice weekly with 2.0ug TPA in 200ul acetone applied 
topically at the same area of DMBA initiation. Mice were scored for papilloma weekly 
and the ones with skin lesions were included in tabulations until their conditions require 
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their withdrawal from the study. Tumor samples will be fixed in formalin, paraffin 
embedded and sectioned for H&E staining. The slides were diagnosed microscopically of 
their malignancy conversions. Data were analyzed by one-way ANOVA and Pearson 
Chi-square using SPSS software (SPSS Inc. Chicago, IL). 
 
2.5 REAL-TIME QUANTITIVE PCR.   
Total RNA from wild type and E2F3 transgenic mice epidermis tissue was 
purified with the TriReagent protocol (MRC, Cincinnati, OH). The quality of RNA was 
checked by on-chip gel electrophoresis (Agilent 2100 Bioanalyzer, Palo Alto, CA). The 
cDNA synthesis was carried out by reverse transcription with 1µg RNA, 100 units 
MMLV reverse transcriptase (Ambion, Austin, TX), 40µmol of dNTPs (Ambion, Austin, 
TX) at 50°C for 95 min in a total volume of 20 µl using 50µM random decamer primers 
(Ambion, Austin TX). The real time quantitive PCR reactions were performed in 25µl 
volumes containing 5-10 ng of cDNA, 1X TaqMan Universal PCR Master Mix (Applied 
Biosystems, Foster City, CA) and 1.25 µl of primers and probes labeled with FAM 
(Applied Biosystems, Foster City, CA). PCR conditions were 95°C for 10 min to activate 
the AmpliTaq Gold DNA polymerase, followed by 40 cycles of 95°C for 15s and 60°C 
for 1min.  The test parameter, Ct value, generated by the ABI PRISM 7700 Sequence 
Detection System software, were analyzed using the arithmetic formula 2-ΔΔ Ct. Mouse 
GAPDH was used as an internal control gene for normalization.  The relative quantitation 
was calculated by dividing the amount of each target gene by the amount of GAPDH in 
each sample.  
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2.6 CELLS AND VIRUSES. 
2.6.1    Mouse embryo fibroblasts (MEF) isolation and culture 
13-14 day pregnant mice were euthanized and their abdomens soaked with 
ethanol.  The string of embryos (in uterus) was removed from the mother and placed in a 
10cm culture dish with 10-20ml PBS. 
The following was done one embryo at a time. Each embryo was removed from 
the uterus.  The placenta and embryonic sac were removed.  The embryo was placed into 
1-2ml clean PBS in a 10cm culture dish separate from the uterus and other embryos.  The 
head was removed and put into a 1.5 ml tube for DNA extraction and genotyping.  The 
blood containing internal organs were removed.  The remaining embryo was placed onto 
the interior side of a 50 ml tube.  The embryo was minced finely with scissors.  Finally, 
10 cold PBS was added to the minced embryo and the tube was placed on ice until all 
embryos were harvested.  
The embryos were then centrifuged (500xG for 5 min) and the PBS was removed 
by aspiration.  Each embryo was resuspended in 7.5 trypsin-EDTA and incubated at 37°C 
in a water bath for 20 minutes with occasional shaking.  Trypsin was then deactivated by 
adding 7.5ml Dulbecco’s modified Eagle’s media (DMEM) with 10% fetal bovine serum 
(FBS) and 1.5xPenicillin/Streptomycin.  The embryos were centrifuged again and the 
supernatant removed by careful pouring.  Pellets were resuspended in 12.5ml DMEM, 
10%FBS, and then poured through a 70µM filter onto a 10cm culture dish, which was 
incubated at 37°C, 5%CO2.  Plates were split 1:3 when confluent.  This first passage was 
then frozen for future use or further passaged for experimentation. 
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All MEF cultures were maintained in DMEM with 10% FBS at 37°C in 5%CO2. 
All experiments using MEFs used cells between passage 3 and 6.   
2.6.2    Primary human fibroblasts 
Primary human dermal fibroblasts from age-, sex-, and ethnicity-matched 
individuals GM08399 (wild type NHFs) and GM02502 (AT cells from an AT patient) 
(Coriell Cell Repositories, Camden, NJ) were maintained in MEM with 2mM glutamine, 
nonessential amino acids, and 15% fetal bovine serum.  
2.6.3    Adenoviral infections 
Recombinant adenovirus expressing human E2F3a and control virus containing 
only CMV promoter were made using the AdEasy adenovirus system (Quantum 
Biotechnologies, Montreal, Canada).  For infections, cells were plated at 5000 cells/cm2 
per 10cm plate and cultured overnight.  Cultures were then incubated in starvation media 
containing 0.5% FBS for 24 hours prior to infection.  On the day of infection, the cells 
were washed, counted and cultured in 3 ml of serum-free medium containing AdE2F3a 
ad AdCMV at the multiplicity of infection (MOI) of 100.  After one hour of infection,  7 
ml of media with 0.5% FBS was added, and the cells were incubated for an additional 24 
hours for the comet assay and 48 hours for apoptosis assay and immunoblotting.  
 
2.7 WESTERN BLOT ANALYSIS.  
Epidermal protein was collected by scrapping dorsal skin and resuspending the 
scrapped off tissue in radioimmunoprecipitation assay (RIPA) buffer [150 mM NaCl, 
1.0% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0), 1 mM 
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phenylmethylsulfonyl fluoride, 50 mM NaF, 50 mM Na3VO4, 2ug/ml aprotinin, 2ug/ml 
leupeptin, 1ug/ml pestatin, 13 mg/ml ß-glycerophosphate, and 12 µg/ml sodium 
vanadate].  Collected samples were frozen in liquid nitrogen immediately and stored in -
80°C. Thawed crude samples were centrifuged to be rid of lipid component and 
unresolved tissue. Centrifuge multiple times if necessary to obtain pure protein samples. 
Protein from primary human fibroblasts and embryonic mouse fibroblasts 
harvested at time indicated post-infection or as described for IR and chemical treatments 
by scraping cells into either RIPA buffer with protease/phosphatase inhibitors or into 3X 
SDS loading buffer (as per the Cell Signaling Technology protocol). Protein obtained in 
RIPA buffer was then quantified using the BCA Protein Assay Kit (Pierce Endogen; no. 
23225). Protein obtained in 3X SDS loading buffer was sonicated prior to further steps.  
Protein samples were then boiled SDS loading buffer and electrophoresis through SDS-
polyacrylamide gels, the resolved proteins are transferred to polyvinylidene difluoride 
(PVDF) membrane (Amersham Biosciences) by electroblotting. Specific proteins were 
detected by standard immunoblotting procedures using the following primary antibodies: 
E2F1 (KH95, sc-251, Santa Cruz Biotechnology), E2F3 (c-18, sc-878) (Santa Cruz 
Biotechnology), phospho-Ser15 p53 (9248; Cell Signaling Technology), phopho-Ser1981 
ATM (200-301-400; Rockland), γH2AX (05-636; Upstate Biotechnology), p19ARF 
(200-501-893, Rockland), ß-actin (H-2350; Santa Cruz Biotechnology), ß-tubulin (H-
235; Santa Cruz Biotechnology).  
 
2.8 CASPASE-3 ACTIVITY ASSAY.  
For caspase 3 activity measurement, cells were washed twice in phosphate-
buffered saline and the whole-cell lysate was made in the lysis buffer (50 mM HEPES, 
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1% Triton X-100, 0.1% 3-[(cholamidopropyl)-dimethylammonio]-1-propanesulfonate 
(CHAPS), 1 mM DTT, and 0.1 mM EDTA) then, 50-100 µg of whole-cell lysate was 
added to a reaction mixture containing 50 µM fluorogenic peptide substrates acetyl-
DEVD-AFC (Ac-DEVD-AFC) (Biomol, Plymouth Meeting, PA). 50 mM HEPES (pH 
7.4), 10% glycerol, 0.1% CHAPS, 100 mM NaC1, 1 mM EDTA, and 10 mM DTT, in a 
total volume of 100 µl and incubated at 37°C for 1 h. Production of AFC was monitored 
in a spectrofluorimeter with an excitation wavelength of 400 nm and an emission 
wavelength of 505 nm. The results were presented as activation increase fold versus that 
of the control. 
 
2.9 γH2AX IMMUNOFLUORESCENCE.  
Formalin fixed, paraffin embedded mouse skin sections were deparaffinized, 
boiled in10mM sodium citrate for 10 min, and blocked in 50% goat serum for 30 
minutes.  Sections were then incubated overnight at 4°C with antibody against histone 
H2AX pS139 (γH2AX) (Upstate Biotechnology) at a 1:300 dilution factor.  Samples 
were washed with phosphate-buffered saline solution for 3 times and incubated with 
Alexa Fluor 488-conjugated goat anti-mouse secondary antibody from Molecular Probes.  
The sections were imaged by Olympus BX60 fluorescent microscope. 
 
2.10 IMMUNOHISTOCHEMICAL STAINING FOR P53 PHOSPHO-SERINE 15. 
Skin sections were fixed in formalin, paraffin embedded, and sectioned.  After 
deparaffinization and hydration, sections were blocked with 3% H2O2 in water for 10 
minutes and then washed. Slides were boiled in 10mM citrate buffer pH 6.0 for 15 
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minutes and after 20 minutes cool down, were blocked in 10% goat serum in phosphate-
buffered saline for 30 minutes.  Skin sections were incubated with primary p53-phospho-
serine15 antibody with a dilution factor of 1:100 (Cell Signaling Technology) for one 
hour at room temperature.  Slides were then washed, incubated with Envision labeled 
polymer, secondary anti-rabbit antibody conjugated with horseradish peroxidase (Dako) 
for 30 minutes at room temperature.  After buffer wash five times, incubate with 
Diaminobenzidine (DAB) for five minutes and then wash, counter stain, dehydrate, 
clear and coverslip slides. Numbers of p53-phospho-serine15 positive cells per 10 mm 
skin were determined microscopically. 
 
2.11 SINGLE-CELL GEL ELECTROPHORESIS (COMET) ASSAY. 
Primary keratinocytes were isolated from newborn mouse epidermis.  Skin 
samples from 2-day-old newborn mice were incubated in trypsin at 4°C overnight, and 
then the epidermal layer was separated from dermis.  Epidermis was then minced with 
scissors in super media (Gibco, Carlsbad, CA) containing 10% FBS and stirred.  Primary 
keratinocytes were plated at 107 / 10cm dish in super media for 2h, then KBM-2 media 
(Cambrex Bio Science, Walkersville, MD) for 2-3 days. Primary keratinocytes at a 
concentration of 2 X 105 cells per ml were then embedded in low-melting-point agarose 
on a glass slide by using the Comet Assay kit and the manufacturer’s protocol (Reign, 
Gaithersburg, MD). Briefly, the embedded cells were incubated overnight at 4°C in 
lysis solution (2.5M NaCl, 100 mM EDTA pH 10, 10 mM Tris, 1% sodium lauryl 
sarcosinate, 0.01% Triton X-100) followed by incubation in alkaline solution (300 mM 
NaOH, 1mM EDTA) for 8 minutes to denature the DNA. The samples were then washed 
twice in 1 X TBE buffer, stained with SYBR Green, and nuclei were visualized by 
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fluorescence microscopy. Olive tail moments of at least 50 nuclei per slide were scored 























Chapter III Deregulated E2F3a induces proliferation, tumorigenesis 
and p53-independent apoptosis in vivo 
3.1 RATIONALE AND SIGNIFICANCE 
            Among the E2F transcription factors, E2F1, E2F2, and E2F3a have been referred 
to as activator E2Fs.  They are important in regulating gene expression at the G1/S phase 
transition of the mammalian cell cycle and are important for cell cycle progression 
(Bagchi et al., 1990; Lavia and Jansen-Durr, 1999).  Several studies done in cell culture 
systems have shown that overexpression of E2F3 can induce quiescent cells to enter S 
phase, and subsequently cell proliferation (DeGregori et al., 1997; Johnson et al., 1993; 
Lukas et al., 1996; Vigo et al., 1999).   More evidence of the importance of E2F3 in 
activating S phase genes and in cell proliferation come from endogenous E2F3 function 
studies. Mouse embryonic fibroblasts that lack E2F3 have a defect in the mitogen 
induced activation of almost all known E2F-responsive genes and this results in impaired 
proliferation of both primary and transformed cells (Humbert et al., 2000).  Furthermore, 
in the E2F3 null mouse models, E2F3 loss has a stronger negative effect on cell 
proliferation compared with the loss of E2F1 and E2F2 (Humbert et al., 2000; Leone et 
al., 1998). Therefore, E2F3a is considered to be a strong positive regulator for cell 
proliferation. It was also shown that following mitogenic induction in primary fibroblasts, 
E2F3a activates most known E2F-resposive genes whose products are rate limiting in 
DNA replication such as Cdc6 and the Mcm proteins (Hateboer et al., 1998; Kowalik et 
al., 1998). Thus, E2F3a is a crucial factor that determines the rate of proliferation in 
primary fibroblasts (Humbert et al., 2000).    
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It has been shown that one or more of the activating E2Fs can trigger cells to 
undergo apoptosis through p53-dependent (Kowalik et al., 1995; Shan and Lee, 1994) or 
p53-independent mechanisms (Hsieh et al., 1997; Irwin et al., 2000). On the other hand, it 
was shown that when overexpressed in REF52 fibroblasts, the induction of apoptosis is a 
specific function of E2F1 (DeGregori et al., 1997; Hallstrom and Nevins, 2003). In other 
experiments, the ectopic expression of E2F1, E2F2 or E2F3 all induce apoptosis in Rat1 
fibroblasts (Vigo et al., 1999). Also E2F3 deficiency severely reduces the inappropriate 
apoptosis observed in several tissues in mouse embryos with inactivated Rb (Saavedra et 
al., 2002; Ziebold et al., 2001). These findings indicate that deregulated E2F3 induces 
apoptosis and E2F3 also plays a role in apoptosis that occurs in the absence of Rb. While 
ectopic expression of E2F3 was reported to induce apoptosis in some experimental 
systems (Vigo et al., 1999) but not in others (DeGregori et al., 1997; Kowalik et al., 
1998), it still remains to be answered if ectopic expression of E2F3a induces apoptosis in 
an in vivo system.   
Based on the in vitro overexpression and loss of function studies, we 
hypothesized that K5 E2F3a mice would exhibit increased epidermal proliferation.  
Based on the previous opposite arguments about E2F3a-induced apoptosis, we are 
interested to determine if E2F3a induces apoptosis in a transgenic mouse model, which 
provides a more physiological environment for addressing the question of whether E2F3a 
induces apoptosis.   More important, we would like to find out the effect of deregulated 
E2F3a in tumor development.  To determine this, we utilized a K5 E2F3a transgenic 
mouse model developed in our laboratory.  By performing a spontaneous tumor study and 




3.2.1    Generation of K5 E2F3a transgenic mice 
The K5 E2f3a construct was made by inserting 1.6 kb of full length human E2f3a 
cDNA into the SnaBI site of pBS-KS-K5 plasmid, which contains the bovine K5 
promoter (Ramirez et al., 1994), the rabbit β-globin intron 2, and the simian virus 40 
polyadenylation signal to ensure proper post- translational processing of the gene (Pierce 
et al., 1998a). The construct is shown in figure 8A (Figure 8A).  The bovine K5 promoter 
fragment directs expression to the basal cell layer of the epidermis, the hair follicles, and 
other stratified squamous epithelia in transgenic mice (Ramirez et al., 1994). The full-
length cDNA was taken from the E2F3a expression vector pcDNA3- E2F3a.  Founder 
transgenic mice were made by microinjecting the purified transgene into the pronuclei of 
zygotes and then by implanting the zygotes into pseudo-pregnant female mice.  Lines 
were established and maintained by backcrossing the founders to the FVB strain.   Two 
lines of K5 E2F3a transgenic mice that overexpress the E2F3a transgene in squamous 
epithelium were established from six original founders. Western blot analysis using 
antiserum that recognizes both mouse and human E2F3 confirmed that these transgenic 
mouse lines have increased expression of E2F3 protein in epidermal tissue (Figure 8B).  
Two dominant bands can be observed in western blot analysis, with the upper band 
corresponding to full-length E2F3a.  The lower band may represent an E2F3b-like 
product that has been shown to be produced from an internal, alternative translation 
initiation site in the E2F3a mRNA (He et al., 2000).  Overexpression of E2F3 was also 
detected by immunohistochemical  staining  of  transgenic   tissue.    In   the   K5 E2F3a 




Figure 8.  Development of K5 E2F3a transgenic mouse lines. 
(A) Schematic representation of the K5 E2F3a transgene with the bovine K5 promoter, 
the rabbit β-globin intron 2, full length human E2F3a cDNA, and the simian virus 40 
polyadenylation signal.  (B) Western blot analysis of the epidermal protein lysates from 
non-transgenic mice (wt) and K5 E2F3a transgenic lines E2F3.2 and E2F3.5 using 
antisera specific to E2F3 and β-actin.  (C) Skin samples from young adult wild type and 
K5 E2F3a (line3.2) mice were immunohistochemically stained using antisera specific for 
E2F3.  The K5 E2F3a transgenic skin is much thicker compared to wild type skin.  The 






Figure 9. Expression of E2F target genes in K5 E2F3a transgenic mice. 
(A) Real-time quantitative PCR was used to measure the expression of p19Arf, cyclin E, 
DNA polymerase α/p68, and p73 in RNA samples from the epidermis of K5 E2F3a 
transgenic (line3.5) and wild type sibling mice.  RNA samples from two mice from each 
genotype were analyzed twice each and normalized to GAPDH expression.  Bars indicate 
standard error; * indicates statistical significance where p < 0.05 compared to wild type.  
(B) Western blot analysis of protein extract isolated from epidermis of K5 E2F3a 






basal layer of the epidermis and in the outer root sheath of hair follicles (Figure 8C right 
panel). Our immunohistochemical staining procedure did not detect endogenous E2F3 in 
nontransgenic tissues from the wild type siblings (Figure 8C left panel). 
To determine if our transgene is functional, we tested if E2F3a overexpression 
resulted in the transcriptional activation of E2F target genes. Real-time PCR was 
performed on RNA samples isolated from the epidermis of K5 E2F3a transgenic mice 
and their wild type siblings.  The expression of cyclin E and p19Arf was increased an 
average of three- and eight-fold respectively in K5 E2F3a transgenic mice compared to 
wild type controls (Figure 9A).  DNA polymerase α/p68 was also moderately upregulated 
in K5 E2F3a transgenic epidermis tissue.  In contrast, the expression of p73, another E2F 
target gene, was not significantly different between wild type and transgenic mice.  This 
suggests that p73 is a transcriptional target for specific E2F family members such as 
E2F1 but is not significantly regulated at the transcriptional level by E2F3a.  To confirm 
the increased expression of ARF at the protein level, Western blot analysis was 
performed using antiserum specific to the exon1β region of the ARF protein (Figure 9B). 
 
3.2.2    Overexpression of E2F3a increases both proliferation and apoptosis 
To examine the effect of deregulated E2F3a on cell and tissue homeostasis, skin 
samples from K5 E2F3a transgenic mice and their wild type siblings were analyzed and 
compared. The epidermis of both K5 E2F3a transgenic lines was found to be hyperplastic 
(Figure 10C upper panels) and hyperproliferative (Figure 10C lower panels). The average 
thickness of the epidermis from line 3.2 and line 3.5 transgenic mice is almost 3 times 
that of the wild type sibling controls  (Figure 10A).  The proliferation index of the 




Figure 10.  Hyperplasia and hyperproliferation in K5 E2F3a transgenic epidermis.  
(A) Epidermal thickness was measured using skin samples from young adult 
nontransgenic mice (wt) and K5 E2F3a transgenic mice from both lines 3.2 and 3.5. Fifty 
random measurements were taken on skin samples from five individual mice of each 
genotype and the average for each genotype is presented.  B. Skin samples from the same 
mice as above were immunohistochemically stained for BrdU incorporation.  The 
percentage of interfollicular basal layer keratinocytes staining for BrdU was calculated 
for each samples and the average for each genotype is presented.  Bars indicate standard 
deviation; *p<0.05 compared to wild type. C. Representative micrographs of skin 
samples used in above measurements.  Upper panels are H&E staining showing the 
increased thickness in the two K5 E2F3a transgenic mice lines 3.2 and 3.5. Lower panels 
are immunohistochemical staining for BrdU showing the increased BrdU incorporation in 












Figure 11. E2F3a-induced p53-independent apoptosis in transgenic epidermis. 
(A) Skin samples from non-transgenic (WT) and K5 E2F3a transgenic mice from each 
line (E2F3.2 and E2F3.5) were immunohistochemically stained for the activated form of 
caspase 3.  The number of caspase 3 positive keratinocytes per 10 mm of skin was 
determined for five individual mice of each genotype and the average for each genotype 
is presented. (B) K5 E2F3a transgenic mice (line 3.5) were crossed into p53 null 
background and skin samples taken from non-transgenic (WT) and K5 E2F3a transgenic 
mice with (p53+/+) and without (p53-/-) functional p53. The average number of caspase 3 
positive cells per 10 mm of skin was determined for each genotype as above. Bars 





with BrdU prior to sacrifice.  Using BrdU incorporation as a marker of S-phase, the 
number of  interfollicular  basal  keratinocytes in S phase  was  then  determined  in  skin 
samples. Approximately three percent of basal layer keratinocytes were in S-phase in 
nontransgenic mice while the proliferation index of line 3.2 and 3.5 transgenic mice was 
nine and 13 percent, respectively (Figure 10B and C). 
 To determine the effect of deregulated E2F3a expression on apoptosis in vivo, 
epidermal cells expressing activated caspase-3 were detected in skin sections by 
imunohistochemistry.  The number of caspase-3 positive cells in both K5 E2F3a 
transgenic lines was significantly increased over the level observed in non-transgenic 
controls (Figure 11A). The TUNEL assay was also performed on skin samples from K5 
E2F3a transgenic mice and agreed with the caspase-3 immunostaining results. This 
feature of E2F3a is similar to E2F1, which when deregulated, also induces elevated levels 
of apoptosis in mouse epidermis.  E2F1-induced apoptosis is dependent on p53 (Pierce et 
al., 1998b).  Even though both E2F3a and E2F1 induced apoptosis, when K5 E2F3a 
transgenic mice were crossed into a p53 null background, the absence of p53 had no 
significant effect on the level of apoptosis observed in K5 E2F3a transgenic epidermis 
(Figure 11B).   This suggests that E2F3a might induce apoptosis using different 
mechanisms than E2F1.   
3.2.3    K5 E2F3a transgenic mice have increased tumor development in both two 
stage and spontaneous tumor assay 
To determine the oncogenic property of E2F3a, a group of K5 E2F3a transgenic 
mice from both lines was maintained with wild type siblings for two years and monitored 
for spontaneous tumor development.  The tumor incidence of K5 E2F3a transgenic mice 
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Figure 12.  Spontaneous tumor development in K5 E2F3a transgenic mice.  
A group of K5 E2F3a transgenic mice from both lines (E2F3.2 and E2F3.5) were 
maintained for two years along with their non-transgenic siblings (wt).  Total tumor 
incidence (A and B) and incidence of K5-positive epithelial tumors (C and D) are 





Figure 13.  Histological appearance of tumors from K5 E2F3a transgenic mice.  
Sections from a mammary carcinoma (A and B) and a squamous cell carcinoma (C and 
D) were stained with hematoxylin and eosin (A and C) or immunohistochemically stained 












Table 1 Spontaneous K5-positive tumors in K5 E2F3a mice 
 
line     sex    age (months)      location                Histological appearance 
 
        
 3.2      M          15                  skin                      Squamous Cell Carcinoma 
 3.2      M          24                  skin                      Papilloma 
 3.2      M          24                  thymus                 Thymoma 
 3.2      F           19                  mammary gland   Carcinoma 
 3.2      F           14                  salivary gland      Adenocarcinoma 
 3.5      F           21                  vagina                  Squamous Cell Carcinoma  
 3.5      F           14                  mammary gland   Carcinoma 
 3.5      F           21                  thymus                 Thymoma 














Figure 14.  K5 E2F3a transgenic mice have an enhanced response to two-stage skin 
carcinogenesis.  
K5 E2F3a transgenic mice from line 3.5 (A) and line 3.2 (B) along with non-transgenic 
sibling controls (wt) were subjected to the two-stage skin carcinogenesis assay.  Skin 
papilloma development was recorded weekly and the average number of papillomas per 
mouse was determined for each group.  (C) Carcinoma development was determined in 
the mice subjected to the two-stage carcinogenesis assay above after 30 weeks of 
promotion and expressed as carcinomas per mouse. Diagnosis by a veterinary pathologist 
confirmed that lesions were squamous cell carcinomas.  Bars indicate standard error; *p 




at two years of age was not statistically different from the incidence of their wild type 
siblings (Figure 12A and B).  However, when tumors of only keratin 5-expressing tissues 
were considered, there was a clear difference between K5 E2F3a transgenic and wild type 
mice (Figure 12C and D). In both lines, approximately 20% of transgenic mice developed 
tumors in K5-expressing tissues by two years of age while none of the wild type mice 
developed tumors in K5-expressing tissues.  All epithelial tumors from K5 E2F3a 
transgenic mice included in Figure 12C and D and listed in Table 1 were confirmed to 
express keratin 5 and overexpress E2F3 as determined by immunohistochemistry (Figure 
13).  The majority of tumors in wild type mice were alveolar bronchiolar adenomas, 
which do not express K5 and are a common background tumor in the FVB strain.  
Despite the fact that E2F3 is overexpressed in human bladder and prostate cancers, no 
tumors in these K5-expressing tissues were observed in K5 E2F3a transgenic mice. 
To further address the role of E2F3a in tumorigenesis, K5 E2F3a transgenic mice 
and their wild type siblings were subjected to a two-stage skin carcinogenesis protocol.  
This carcinogenesis assay is one of the most common models for studying multistage 
tumor development.  Initiation of carcinogenesis was carried out by a single topical 
application of 7, 12-dimethylbenz[a]anthracene (DMBA) to the dorsal skin of six- to 
eight-week old mice.  DMBA induces a mutation at codon 61 of the c-Ha-ras gene in 
initiated cells.  From the beginning of the third week after DMBA treatment, 12-O-
tetradecanoylphorbol-13-acetate (TPA) was applied to the initiated area twice a week for 
a total of 20 weeks.  This promotion process results in hyperplasia of the skin and 
eventually the outgrowth of exophytic papillomas.  A subset of these benign papillomas 
can convert to malignant skin carcinomas.  By 20 weeks of promotion, both lines of K5 
E2F3a transgenic mice developed approximately twice as many skin papillomas as the 
wild type sibling control group (Figure 14A and B).  The multiplicity of carcinomas at 30 
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weeks of promotion was slightly higher in both K5 E2F3 transgenic lines compared to 
wild type controls (Figure 14C).  The above results suggest that E2F3a functions as an 
oncogene in vivo. When it is deregulated, E2F3a induces tumor development both 
spontaneously and with carcinogenic chemical stimulation. 
 
3.3 DISCUSSION 
Most human cancers have a disruption in the p16INK4a-cyclin D-RB pathway 
resulting in the deregulation of activator E2Fs, among them E2F3a.  Several studies have 
shown amplification of the E2f3 gene and/or increased E2F3 expression in human 
cancers including transitional cell carcinoma of the bladder and prostate cancers (Feber et 
al., 2004; Foster et al., 2004; Oeggerli et al., 2004). Also E2F3a is used as a marker for 
large-cell lung cancer (Borczuk et al., 2003). This is consistent with the finding that E2F3 
overexpression can stimulate cell proliferation and contribute to oncogenic 
transformation in vitro (DeGregori et al., 1997; Xu et al., 1995). In a mouse model with 
Rb–deficient tumors, E2f3 loss results in suppression of pituitary tumors but promotes the 
development and metastasis of medullary thyroid carcinomas (Ziebold et al., 2003). This 
suggests that E2F3 activity is a key event for tumorigenesis downstream of Rb loss in 
some tissues. At the same time, E2F3 may also have tumor suppressive activity in 
different Rb mutant tumors. In human tumors, the inactivation of E2f3 has not been 
reported, so the relevance of this tumor suppressive activity for E2F3 is unclear.   
The K5 E2F3a transgenic model was generated to examine the role of deregulated 
E2F3a in cell proliferation and apoptosis in an in vivo system, and more importantly, to 
explore the role of E2F3a in tumorigenesis.  In this model, E2F3a is ectopically expressed 
in a number of epithelial tissues starting at day 13 of embryonic development (Ramirez et 
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al., 1994).  In the epidermis, overexpression of E2F3a leads to hyperproliferation and 
hyperplasia as well as an increased level of apoptosis.   In a previous study in which 
E2F3a is inducibly expressed in the pituitary gland, the induction of E2F3a led to 
hyperproliferation and hyperplasia but the sustained overexpression of E2F3a did not 
result in tumor formation (Denchi et al., 2005).  In our K5 E2F3a transgenic model, 
overexpression of E2F3a did modestly induce tumor development in some epithelial 
tissues.  Furthermore, the K5 E2F3a transgenic mice have an increased sensitivity to 
chemical carcinogenesis in the DMBA/TPA two-stage assay.   
Among the E2F family members that have been tested in the K5 transgenic 
model, E2F3a as well as E2F1 induce apoptosis while E2F4 lacks this apoptosis inducing 
activity, yet, all three members induce hyperproliferation and hyperplasia in the 
epidermis.  Even though both E2F3a and E2F1 induce apoptosis, E2F1 induced apoptosis 
is largely p53 dependent as shown by reduced levels of apoptosis after inactivation of 
p53, while the inactivation of p53 does not affect E2F3a-induced apoptosis.  This 
suggests that E2F3a and E2F1 utilize different mechanisms to induce apoptosis.  In this 
K5 transgenic mouse model, E2F3a also displays different oncogenic properties than that 
of E2F1 and E2F4.  K5 E2F3a transgenic mice develop epithelial tumors that are not 
observed in wild type siblings.  These tumors develop late in life starting at 14 months of 
age and at a relatively low incidence. K5 E2F1 transgenic mice develop spontaneous 
epithelial tumors starting at about one year of age and these mice have a higher incidence 
of tumor formation (Pierce et al., 1999).  On the other hand, E2F4 transgenic mice are not 
predisposed to developing tumors (Wang et al., 2000).  It is possible that the level of E2F 
protein expression differs among these models and that this explains the difference in 
tumor development.  However, we do not believe this is the case since the levels of 
hyperproliferation and hyperplasia are similar or higher in the E2F4 and E2F3 transgenic 
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models compared to K5 E2F1 transgenic mice (Bartkova et al., 2005; Pierce et al., 1998a; 
Wang et al., 2000).  As mentioned earlier, both E2F1 and E2F3 have been shown to have 
tumor suppressive activities.  In the two-stage carcinogenesis assay, K5 E2F1 transgenic 
mice are resistant to tumor development compared to the wild type siblings. (Pierce et al., 
1999).  In contrast to K5 E2F1 transgenic mice, K5 E2F3a transgenic mice are more 
sensitive to two-stage carcinogenesis than wild type mice.  While this finding further 
demonstrates that deregulated E2F3a activity can contribute to tumor development, it also 

















Chapter IV Characterizing E2F3a apoptotic pathways 
4.1 RATIONALE AND SIGNIFICANCE 
 One of the novel but established functions of E2F3a is its apoptotic activity.  
E2F3 has been shown to contribute to apoptosis in several tissues in Rb mutant embryos 
(Saavedra et al., 2002; Ziebold et al., 2001).  Even though some overexpression studies 
suggested that apoptosis is a specific property of E2F1 (DeGregori et al., 1997; Kowalik 
et al., 1998; Lissy et al., 2000), other cell culture and recent in vivo mouse model studies 
demonstrate that ectopically expressed E2F3a induces apoptosis in vitro and in vivo  
(Lazzerini Denchi and Helin, 2005; Paulson et al., 2006). 
 In the classical E2F apoptosis pathway, deregulation of E2F1 transactivates the 
Arf tumor suppressor gene (Bates et al., 1998; Robertson and Jones, 1998).  ARF 
interacts with Mdm2 and inhibits its ability to target p53 for degradation (Kamijo et al., 
1998; Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998).  Thus, increased 
levels of ARF mediated by E2F1 results in p53 stabilization and accumulation to induce 
apoptosis. However, several reports demonstrate that deregulated E2F1 induces apoptosis 
in a p53-dependent but ARF-independent manner (Rogoff et al., 2002; Russell et al., 
2002; Tolbert et al., 2002; Tsai et al., 2002).  In the absence of ARF, E2F1-induced 
apoptosis is correlated with p53 phosphorylation by the ATM kinase (Rogoff et al., 2002; 
Rogoff et al., 2004).  However, the mechanism of how E2F1 activates ATM is unclear.  
Currently, a pathway of E2F1-induced apoptosis that is mediated by ATM kinase is 
becoming accepted.  ATM is a serine/threonine kinase that belongs to the 
phosphatidylinositol 3 kinase-like kinase (PIKK) family. In response to DNA double-
strand breaks (DSBs), ATM directly phosphorylates p53 on serine15 (Banin et al., 1998; 
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Canman et al., 1998; Tibbetts et al., 1999) and indirectly promotes the phosphorylation of 
p53 on other residues by phosphorylating and activating additional kinases such as Chk1, 
Chk2 and Plk3 (Ahn et al., 2000; Gatei et al., 2003; Xie et al., 2001).  Phosphorylation of 
p53 at N-terminal residues inhibits Mdm2 binding, increases p53 transcriptional activity 
and stimulates other posttranslational modifications that regulate DNA binding.  
Recent reports have demonstrated that a number of oncogenic factors, such as 
E2F1, cyclin E, and Myc, stimulate the phosphorylation of p53 and some other ATM 
targets (Bartkova et al., 2005; Lindstrom and Wiman, 2003; Powers et al., 2004; Vafa et 
al., 2002). Consistent with these findings, the ATM DNA damage response pathway has 
been shown to be activated early during the formation of several types of human tumors 
(Bartkova et al., 2005; Bartkova et al., 2006; Gorgoulis et al., 2005).  It has been 
speculated that the activation of this checkpoint response by oncogenic stress is a 
mechanism to inhibit the formation or progression of cancer.  In chapter III, we 
demonstrated that transgenic expression of E2F3a induces spontaneous tumor formation 
in vivo and increases sensitivity to the two-stage carcinogenesis assay (Paulson et al., 
2006).  These findings demonstrate an oncogenic property for E2F3a. To address the 
relationship between the oncogenic and apoptotic activity of E2F3a, we first need to 
understand the mechanisms and pathways of E2F3a induced apoptosis.  We show here 
that E2F3a-induces apoptosis by activating the ATM DNA damage response pathway. 
ARF and E2F1 also contribute to E2F3a induced apoptosis in vivo and in human cells.  
Taken together, E2F3a induces apoptosis through multiple pathways. Among these 
pathways, the loss of ATM has the strongest impact on apoptosis impairment.   The 
interactions between the different pathways are not completely clear, but we show here 




4.2.1    Overexpression of E2F3a induces markers of DNA double-strand breaks in 
vivo 
ATM kinase has been considered to be activated by genotoxic stress. However, 
several recent studies show that oncogenic signals also activate ATM to induce cell cycle 
checkpoint responses, which lead to apoptosis or senescence (Bartkova et al., 2005; 
Bartkova et al., 2006; Gorgoulis et al., 2005).  These findings indicate that oncogenic 
signals and genotoxic stress might be more inter-related, and cause similar end effects on 
DNA to activate the ATM pathway.  In chapter III we used a transgenic mouse model 
expressing E2F3a in squamous epithelial tissues to demonstrate that deregulated 
expression of E2F3a leads to hyperproliferation, apoptosis and spontaneous tumor 
development (Paulson et al., 2006). To determine if expression of E2F3a, as an 
oncogenic stress, causes DNA damage in vivo, we examined markers of the DNA 
damage response (DDR) in K5 E2F3a transgenic tissue. One of the most widely used 
markers of DDR is the phosphorylated form of the histone variant H2AX, known as 
γH2AX (Celeste et al., 2003; Lukas et al., 2003; Lukas et al., 2004; Mochan et al., 2004; 
Stucki and Jackson, 2004). γH2AX is induced by IR (ionizing irradiation), a potent 
inducer of DSBs. No γH2AX foci were observed in wild type epidermis while in IR 
treated epidermis, the formation of γH2AX nuclear foci were readily apparent (Figure 
15).  Similar to what is observed in IR treated tissue, γH2AX foci were also present in 
untreated K5 E2F3a transgenic epidermis.  
A number of kinases have been reported to phosphorylate H2AX in response to 








Figure 15.  Deregulated E2F3a induces DNA damage marker γH2AX foci formation 
in vivo 
Immunofluoresent staining was performed on skin sections using antibody specific for 
γH2AX.  (A) Untreated wild type epidermis has undetectable γH2AX foci. (B) Obvious 
γH2AX foci formation in the epidermis from wild type mice exposed to 3 Gy of IR, and 
kept alive for 20 minutes before killing. (C) K5 E2F3a transgenic mice wild type for Atm 
has increased γH2AX foci in epidermis as IR treated mice while (D) K5 E2F3a 








Figure 16.  Overexpression of E2F3a activates ATM in K5 E2F3a transgenic mice 
and in human cell cultures. 
(A) Western blot analysis for ATM-phospho-serine 1981 and tubulin was performed 
using protein extract from mice with genotypes as indicated.  E2F3 expression was 
confirmed using E2F3 specific antisera to these protein extracts.  K5 E2F3a transgenic 
epidermis null for Atm has almost undetectable levels of phospho-serine 1981 level, 
while K5 E2F3a transgenic epidermis wild type for Atm has significantly increased level 
of phospho-serine 1981 compared to wild type control mice.  (B) Skin sections from mice 
with genotypes as indicated were immunochemically stained using p53-phospho-serine 
15 specific antisera.  Positively stained basal layer keratinocytes were calculated 
microscopically.  K5 E2F3a transgenic mice null for Atm had much reduced level of p53-
phospho-serine 15 positive cells compared to K5 E2F3a transgneic mice wild type for 
Atm (*p < 0.01).  (C) Cell lysates were extracted from NHFs and AT cells that were 
infected with control adenovirus (AdCMV) and E2F3a expressing adenovirus (Ad 
E2F3a).  Etoposide (Eto), a DNA damage-inducing agent was used as a positive control. 
AdE2F3a infected NHFs has elevated levels of ATM-phospho-serine 1981 and p53-
phospho serine 15 while AT cells lack both.
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foci formation, K5 E2F3a transgenic mice were crossed into an Atm-/- background.  In the 
absence of ATM, γH2AX immunostaining was much reduced in E2F3a transgenic 
epidermis.  This suggests that when overexpressed, E2F3a signals to ATM directly or 
indirectly, and the activated ATM mediates the phosphorylation of H2AX in response to 
deregulated E2F3a (Figure 15). 
Another well established marker of DSB and ATM activation is 
autophosphorylation of ATM at serine 1981 (Bakkenist and Kastan, 2003). To further 
confirm activation of ATM by overexpression of E2F3a and determine the mechanism of 
E2F3a induced apoptosis, western blot analysis was performed using mouse epidermal 
lysates and a phospho-specific antibody to ATM to demonstrate that transgenic 
expression of E2F3a did indeed lead to ATM phosphorylation at serine 1981 (Figure 
16A).  We also examined phosphorylation of p53 at serine 15, a direct target of ATM 
kinase, in E2F3a transgenic tissue by immunohistochemistry.  Consistent with the finding 
that E2F3a induces the phosphorylation of ATM at serine 1981, K5 E2F3a transgenic 
epidermis showed increased staining for phospho-p53 at serine15 in the basal layer of the 
epidermis and hair follicles compared to wild type mice (Figure 16B).  Inactivation of 
Atm in E2F3a transgenic mice reduced the level of phospho-p53 staining to background 
levels.  In normal human fibroblasts (NHFs), overexpression of E2F3a also induced the 
autophosphorylation of ATM at serine 1981 and the phosphorylation of p53 at serine 15.  
This response was similar to the response observed in NHFs treated with the DNA 
damaging drug etoposide.  As in transgenic tissue, the phosphorylation of p53 in response 
to E2F3a expression was dependent on ATM since it did not occur in primary fibroblasts 
isolated from an AT patient, which lack functional ATM (Figure 16C).  Taken together, 
these findings demonstrate that E2F3a overexpression in K5 E2F3a transgenic mice and 
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in human cells leads to the activation of ATM and the phosphorylation of downstream 
targets H2AX and p53.   
 
4.2.2    Deregulated expression of E2F3a causes DNA damage.   
The ATM kinase plays a pivotal role in the immediate response of cells to DSBs 
but it can also respond to other stresses that do not involve DNA damage.  To determine 
if deregulated E2F3a activity causes DNA damage as the mechanism of activating ATM, 
we used the single cell gel electrophoresis (comet) assay.  Relatively few primary 
keratinocytes isolated from wild type mice exhibited comet tails, indicating little DNA 
damage in these cells.  In contrast, primary keratinocytes isolated from K5 E2F3a 
transgenic mice showed a much-increased percentage of cells with visible comet tails.  
Calculations of the average olive tail moment, a measure of both the amount and 
distribution of DNA in the tail, confirmed that E2F3a transgenic keratinocytes had 
significantly increased DNA damage compared to wild type keratinocytes (Figure 17A).  
To confirm and extend this finding to human cells, we overexpressed E2F3a in NHFs 
using recombinant adenovirus expressing E2F3a and performed the comet assay.  
Consistent with the results from the transgenic keratinocytes, NHFs infected with E2F3a 
expressing adenovirus exhibited increased levels of DNA damage compared to NHFs 
infected with a control adenovirus vector (Figure 17B).  Our laboratory has also shown 
that deregulation of endogenous E2F3 contributes to DNA damage (unpublished data).  
Specifically, expression of the E1A oncoprotein, which binds and inactivates RB, 
significantly increased levels of DNA damage compared to control cells. When E1A 




Figure 17.  Deregulated E2F3a induces DNA damage in primary keratinocytes and 
human cell cultures as measured by the comet assay. 
(A) Primary keratinocytes obtained from the epidermis of newborn K5 E2F3a transgenic 
mice and sibling wild type mice were subjected to the comet assay.  The percentage cells 
with tails were counted microscopically and the average tail moment was analyzed using 
CometScore software from TriTek. (B) Normal human fibroblasts were infected with 
control and E2F3a expressing adenovirus. Post-24 hours of infection, cells were 





knock down E2F3 expression, the level of DNA damage observed in E1A expressing 
cells was reduced while a control siRNA had no effect. 
 
4.2.3    E2F3a-induced apoptosis is dependent on ATM in K5 E2F3a transgenic mice 
and in human cell cultures. 
To establish the relevance of the ATM DNA damage response pathway to E2F3a 
induced apoptosis, tissue from wild type and K5 E2F3a transgenic mice homozygous or 
nullizygous for Atm were examined.  Epidermal cells expressing the activated form of 
caspase 3 were detected in skin samples by immunohistochemistry as a measure of 
apoptosis.  As previous shown (Paulson et al., 2006),  the number of caspase 3 positive 
cells in K5 E2F3a transgenic epidermis is significantly increased over the level seen in 
wild type sibling epidermis (Figure 18B).  This increase in the level of apoptosis was 
largely abolished in transgenic epidermis when Atm was inactivated, while 
hyperproliferation was not significantly affected by the absence of ATM (Figure 18A and 
B).  The importance of ATM in E2F3a induced apoptosis was also tested in primary 
human cell cultures.  NHFs and AT fibroblasts were infected with a control adenovirus 
vector or with adenovirus expressing E2F3a.  As in transgenic epidermis, E2F3a 
overexpression induced a significantly increased level of apoptosis in NHFs while AT 
fibroblasts were relatively resistant to the apoptotic effects of E2F3a (Figure 18 C and D).  





Figure 18.  Inactivation of Atm reduces apoptosis in K5 E2F3a transgenic mice and 
human cell cultures. 
(A) Skin sections taken from mice with the indicated genotypes were 
immunohistochemically stained for BrdU incorporation.  The percentage of interfollicular 
basal layer keratinocytes staining for BrdU was calculated microscopically for each 
sample.  At least 1000 basal layer cells from three or four different sections of the same 
skin sample were calculated.  The average from five independent mice in each genotype 
is presented. The loss of ATM does not affect the BrdU incorporation level induced by 
E2F3a. (B) Skin sections from mice as above were immunohistochemically stained with 
an antibody specific for the activated form of caspase-3.  The average number of positive 
epidermal interfollicular basal layer cells per 10 mm of skin was determined 
microscopically.  The reduction in the number of caspase-3 positive cells in K5 E2F3a 
transgenic mice null for Atm is statistically significant compared to the number in K5 
E2F3a trangenic  mice wild type for Atm (*p < 0.01).  (C) Western blot analysis of 
protein lysates from NHF and AT cells infected with E2F3a expressing adenovirus 
(E2F3a) (lane 2 and 4) and control virus (CMV) (lane 1 and 3) using antisera specific for 
E2F3 and β-actin.   (D) Caspase-3 activity assay performed on cell lysates from NHF and 
AT cells.  Each genotype of cells were infected with control adenovirus (CMV) or E2F3a 
expressing adenovirus (E2F3a). Caspase-3 activity was measured by fluorescence 
intensity of digested caspase-3 substrate AFC-DEVD using FL600 fluorescence reader.  
The fold increase of caspase-3 activity in E2F3a overexpressing AT cells were 















4.2.4    Replication inhibition reduces E2F3a induced DNA damage and ATM 
mediated apoptosis 
                Several mechanisms have been suggested to contribute to DNA damage 
response, including ROS accumulation (Calviello et al., 2006; Vafa et al., 2002), 
telomere attrition (d'Adda di Fagagna et al., 2003; Reaper et al., 2004) and aberrant 
replication induced replication stress (Bartkova et al., 2005; Bartkova et al., 2006; 
Gorgoulis et al., 2005).  To determine if E2F3a-induced DNA damage and following 
responses involve aberrant DNA replication, we used the DNA polymerase α inhibitor 
aphidicolin to inhibit DNA replication.  Indeed, the DNA damage measured by the comet 
assay revealed that in the presence of aphidicolin, E2F3a induced much shorter comet 
tails and less DNA damage represented by decreased olive moment (Figure 19).  In 
eukaryotic cells, Cdk activity is required for initiation of DNA replication.  After 
assembly of the pre-initiation replication complex (pre-RC), Cdk phosphorylates the pre-
RC component Cdc6 and ORC to recruit all the DNA replication proteins to the 
replication fork (Brown et al., 1997; Elsasser et al., 1996) and promotes the origin firing 
and DNA synthesis.  To explore whether Cdk activity was involved in DNA damage and 
apoptosis as a result of E2F3a overexpression, the p21 Cdk inhibitor was co-expressed in 
NHFs.  Continued overexpression of p21 significantly reduced E2F3a-induced DNA 
damage (Figure 20A). The activation of the ATM signalling pathway represented by 
ATM autophosphorylation at serine 1981 and the phosphorylation of its down stream 
targets p53 at serine 15 and γH2AX are also impaired (Figure 20B).  Significantly, 







Figure 19.  DNA replication inhibitor Aphidicolin reduces E2F3a-induced DNA 
damage. 
NHFs were infected with a recombinant adenovirus expressing control vector, or E2F3a.  
At the same time, cells were treated with DNA replication inhibitor Aphidicolin (aph) at 
5µg/ml.  Cells were subjected to the comet assay post-24 hours of treatments. DNA 
damage was measured by olive moment which was analyzed as in Figure 17.  
Aphidicolin treatment significantly reduced DNA damage induced by E2F3a 










Figure 20.  Overexpression of Cdk inhibitor p21 reduces E2F3a-induced DNA 
damage and response. 
(A) NHFs infected with recombinant adenovirus expressing control vector, p21, E2F3a 
and E2F3a plus p21. 24 hours post-infection, cells were subjected to the comet assay.  
DNA damage is represented by olive tail moment.  (B) Cell lysates were extracted from 
cells infected with above adenoviruses post-48 hours of infection.  Immunoblot analysis 
was carried out using antibodies specific for phospho-ATM serine 1981, phospho-p53 
serine 15 and γH2AX.  β-actin serves as a loading control.  (C) Whole cell lysates from 






4.2.5    E2F3a activates ATM independent of E2F1 or p19ARF. 
It has been shown that the E2f1 gene promoter region contains E2F DNA-binding 
sites and that it is an established downstream target of E2F transcriptional activity 
(Johnson et al., 1994). Furthermore, several E2Fs including E2F3 induces E2F1 
expression by binding to the E2F sites in the promoter region of the E2f1 gene and 
activating its promoter (Araki et al., 2003; Neuman et al., 1994; Wells et al., 2000).  This 
inter-regulating ability of E2F family members may explain the phenomenon that the E2F 
transcription factors have their specific yet sometimes overlapping roles in cell 
proliferation, apoptosis, differentiation and development.   
Previous studies have suggested that among the E2F family, E2F1 is a unique 
inducer of apoptosis.  In fact, in cases where E2F3a induces apoptosis, it has been 
suggested that this occurs through the E2F3a-mediated activation of E2F1 (Lazzerini 
Denchi and Helin, 2005).  We and others have demonstrated that E2F1-induced apoptosis 
is also dependent on ATM (Powers et al., 2004; Rogoff et al., 2004), although the 
mechanism of how E2F1 activates ATM is not clear.  Nonetheless, these findings suggest 
the possibility that E2F3a could activate ATM and induce apoptosis through the 
upregulation of E2F1.   
To determine whether E2F3a could activate ATM through the regulation of E2F1, 
we first confirmed that overexpression of E2F3a upregulates endogenous E2F1 
expression at the protein level in both the E2F3a transgenic mouse model (Figure 21A) 
and in normal human fibroblast cultures infected with a recombinant adenovirus 
expressing E2F3a (Figure 21B).  These findings are consistent with the fact that the E2f1 





Figure 21.  Overexpression of E2F3a upregulates endogenous E2F1 protein level. 
(A) Western blot analysis of protein extract isolated from the epidermis of K5 E2F3a 
transgenic mice line3.2 (E2F3.2, lane 2 and 3), line 3.5 (E2F3.5, lane 4 and 5) and wild 
type sibling mice (wt, lane1) using antisera specific for E2F3, E2F1 or β-actin. (B) 
Primary human fibroblasts, NHF (Normal Human Fibroblast) and AT (Fibroblasts from 
AT patients with non-functional ATM) were infected with E2F3a expressing adenovirus 
(lane 3 and 6) and control virus (lane 1 and 4).  Etoposide (Eto) treated NHF and AT cells 
served as a DNA damage treatment control (lane 2 and 5).  Protein lysates from the above 
treated cells were subjected to western blotting analysis with antisera specific for E2F3, 





Figure 22.  E2F3a induces E2F1-dependent apoptosis in vivo and in vitro. 
(A) Skin sections taken from mice with the indicated genotypes were 
immunohistochemically stained for BrdU incorporation.  The percentage of interfollicular 
basal layer keratinocytes staining for BrdU was calculated microscopically for each 
sample.  The average from five independent mice in each genotype is presented.  (B) 
Skin sections from mice as above were immunohistochemically stained with an antibody 
specific for the activated form of caspase 3.  The average number of positive epidermal 
interfollicular basal layer cells per 10 mm of skin was determined microscopically.  The 
number of caspase 3 positive cells in K5 E2F3a transgenic mice null for E2f1 is 
significantly reduced compared to the number in K5 E2F3a trangenic  mice wild type for 
E2f1 (*p < 0.01).  (C) Western blot analysis of protein lysates from MAFs, with genotype 
as indicated, infected with E2F3a expressing adenovirus (E2F3a) (lane 2 and 4) and 
control virus (CMV) (lane 1 and 3) using antisera specific for E2F3 and β-actin.   (D) 
Caspase-3 activity assay performed on cell lysates from MEFs with genotypes as 
indicated.  Each genotype of cells were infected with control adenovirus (CMV) or 
E2F3a expressing adenovirus (E2F3a). Caspase 3 activity was determined by measuring 
digested caspase-3 substrate AFC-DEVD fluorescence intensity in each sample using 
FL600 fluorescence reader.  The fold increase in caspase-3 activity in E2F3a 
overexpressing cells null for E2f1 was significantly reduced compared to E2F3a 










Figure 23.  E2F3a activates ATM independent of E2F1.  
(A) MEFs with genotype as indicated were infected with control virus (CMV) and 
adenovirus expressing E2F3a (E2F3a).  IR irradiation is used as DNA damage positive 
control.  Cell lysates from above treated cells were subjected to western blot analysis 
with specific antisera to E2F3, E2F1, phospho-p53 serine 15 and phospho-ATM serine 
1981. Actin serves as loading control.  E2F3a overexpressing cells wild type or null for 
E2f1showed little difference in the level of phospho-ATM and phospho-p53.  (B) γH2AX 
foci formation shown by immunofluoresent staining using antibody specific for γH2AX.  
Skin sections were obtained from mice with genotype as indicated.  IR irradiated skin 
section serves as a positive control.  The loss of E2F1 did not affect E2F3a induced 














Figure 24. Inactivation of Arf reduces apoptosis in vivo and in vitro. 
(A) Skin sections taken from mice with the indicated genotypes were 
immunohistochemically stained for BrdU incorporation.  The percentage of interfollicular 
basal layer keratinocytes staining for BrdU was calculated microscopically for each 
sample.  At least 1000 basal layer cells from three or four different sections of the same 
skin were calculated.  The average from five independent mice in each genotype is 
presented. (B) Skin sections from mice as above were immunohistochemically stained 
with an antibody specific for the activated form of caspase-3.  The average number of 
positive epidermal interfollicular basal layer cells per 10 mm of skin was determined 
microscopically.  The reduction in the number of caspase-3 positive cells in K5 E2F3a 
transgenic mice null for Arf is statistically significant compared to the number in K5 
E2F3a transgenic mice wild type for Arf (*p < 0.01).  (C) Western blot analysis of protein 
lysates from MEFs, with genotype as indicated, infected with E2F3a expressing 
adenovirus (E2F3a) (lane 2 and 4) and control virus (CMV) (lane 1 and 3) using antisera 
specific for E2F3 and β-actin.   (D) Caspase-3 activity assay performed on cell lysates 
from MEFs with genotypes as indicated.  Each genotype of cells were infected with 
control adenovirus (CMV) or E2F3a expressing adenovirus (E2F3a). Caspase-3 activity 
was determined by measuring fluorescence intensity of digested caspase-3 substrate 
AFC-DEVD in each sample using FL600 fluorescence reader.  The fold increase of 
caspase-3 activity in E2F3a overexpressing cells null for E2f1 were significantly 









 target of E2F transcriptional activity (Araki et al., 2003; Neuman et al., 1994; Wells et 
al., 2000). 
            To further address the role of E2F1 in E2F3a induced apoptosis, we crossed K5 
E2F3a transgenic mice and wild type siblings into an E2f1-/-  background.  Inactivation of 
E2f1 did not affect the ability of E2F3a to stimulate cell proliferation as indicated by 
similar levels of BrdU incorporation in K5 E2F3a transgenic epidermis in the presence or 
absence of E2F1 (Figure 22A).  In contrast, inactivation of E2f1 significantly reduced the 
level of apoptosis observed in K5 E2F3a transgenic epidermis (Figure 22B).  To confirm 
these findings in a cell culture system, primary mouse embryonic fibroblasts (MEFs) 
isolated from wild type and E2f1-/- mice were infected with either a control virus or one 
containing E2F3a.  As in epidermial tissue, inactivation of E2f1 reduced the level of 
apoptosis induced by E2F3a in these cultured cells (Figure 22C and D).   
            To determine if the E2F1 dependency of E2F3a-induced apoptosis is connected to 
ATM pathway activation, we examined ATM serine 1981 and p53 serine 15 
phosphorylation in wild type and E2f1-/- MEFs infected with adenovirus expressing 
E2F3a.  MEFs treated with IR served as a positive control for ATM pathway activation.  
Western blot analysis showed no difference in ATM or p53 phosphorylation between 
wild type and E2f1-/- cells overexpressing E2F3a (Figure 23A).  Consistent with those 
findings, γH2AX foci formation in the epidermis of K5 E2F3a epidermis was unaffected 
when E2f1 was inactivated (Figure 23B).  In summary, these findings suggest that while 
E2F1 participates in E2F3a-induced apoptosis, E2F1 is dispensable for ATM pathway 
activation in response to E2F3a.  
            ARF stabilizes and activates p53 by interacting with and inhibiting the p53 
inhibitor Mdm2 E3 ubiquitin ligase (Kamijo et al., 1998; Zhang et al., 1998).  Newer 
findings suggest that E2F1 induces ARF-independent ATM-dependent apoptosis (Russell 
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et al., 2002; Tolbert et al., 2002; Tsai et al., 2002).  The ATM kinase and tumor 
suppressor ARF play major roles in tumor surveillance. ARF is induced by 
hyperproliferative signals emanated from oncogenes, this induction of ARF will 
eventually lead to cell cycle arrest and apoptosis or senescence. Recently multiple studies 
have shown that oncogenic signals also activate ATM checkpoint responses to induce 
apoptosis or senescence (Bartkova et al., 2005; Bartkova et al., 2006; Gorgoulis et al., 
2005).  This suggests that genotoxic stress and oncogenic signals are more tightly 
interrelated than initially thought.  
The ARF tumor suppressor is a transcriptional target of E2F3 and we have shown 
that ARF expression is upregulated in K5 E2F3a transgenic mice (Paulson et al., 2006).  
It has been suggested that ARF contributes to ATM activation (Aslanian et al., 2004).  To 
examine the  role  of ARF  in  E2F3a-induced  apoptosis and ATM activation,  K5 E2F3a  
transgenic mice were crossed into an Arf null background.  Apoptosis in K5 E2F3a 
transgenic epidermis was reduced by Arf inactivation while hyperproliferation was 
unaffected by the absence of ARF (Figure 24A and B).  A similar defect in E2F3a-
induced apoptosis was observed in Arf-/- MEFs infected with an adenovirus encoding 
E2F3a (Figure 24C and D).  In summary, even though E2F3a induced apoptosis is p53-
independent, E2F3a-induced apoptosis is impaired in the absence of ARF.  
            Having established that E2F3a-induced apoptosis is partially dependent upon 
ARF in both in vivo and in vitro systems, we next examined whether ARF was involved 
in ATM activation in response to E2F3a. Wild type and Arf-/- MEFs were infected with 
control or E2F3a expressing recombinant adenovirus and ATM autophosphorylation was 
examined as a marker of ATM pathway activation.  No difference in ATM 
autophosphorylation was observed between wild type and Arf-/- cells overexpressing 






Figure 25.  E2F3a activates ATM independent of ARF. 
Wild type and Arf-/- MEFs obtained from sibling embryos were infected with control 
adenovirus (CMV) or adenovirus expressing E2F3a (E2F3a).  Cell lysates were subjected 
to western blot analysis using antisera to E2F3, phospho-ATM-serine1981 and actin.  No 
obvious difference in the level of phospho-ATM in E2F3a overexpressing cells null for 















Figure 26.  Expression of p19ARF increases in K5 E2F3a transgenic epidermis with 
wild type or E2f1 null background. 
Whole RNA was extracted from mouse epidermis with genotype as indicated.  Real time 
PCR was performed on samples obtained from at least three mice from each genotype.  
The relative expression value was normalized to GAPDH expression.   In both wild type 
and E2f1-/- MEFs, E2F3a overexpression induced similar folds of increase of ARF 
expression compared to controls, but E2f1 inactivation reduced both basal level and 





Figure 27.  Loss of both p53 and p73 impairs E2F3a-induced apoptosis.  
(A) MEFs with genotypes as indicated were infected with recombinant adenovirus 
expressing E2F3a or control virus. Whole cell lysates was extracted 48 hours post 
infection. A caspase 3 activity assay was carried out with AFC-DEVD as a substrate of 
caspase 3.  The activity is represented by the intensity of fluorescence.  (B) Wild type and 
c-Abl null MEFs were extracted from the same litter embryos.  Both genotypes of MEFs 
were infected with control and E2F3a expressing adenovirus and caspase 3 activity 










ATM, E2F1 and ARF for the efficient induction for apoptosis in both transgenic mouse 
epidermis and in primary fibroblasts cultures but that E2F1 and ARF are not involved in 
ATM pathway activation in response to E2F3a overexpression.  Further, K5 E2F3a 
upregulates ARF expression level to the same extent in the presence or absence of E2F1 
(Figure 26). This further indicates that E2F3a utilizes a complicated mechanism that 
involves several parallel pathways instead of a linear apoptosis pathway (Figure 28). 
 
4.2.6    E2F3a induced apoptosis requires either p53 or p73 
We and others have previously demonstrated that E2F3a-induced apoptosis in vivo is 
unaffected by the absence of p53 (Figure 11) (Lazzerini Denchi and Helin, 2005; Paulson 
et al., 2006).  This leaves an apparent paradox since it is believed that p53 is a critical 
mediator of apoptosis downstream of ATM, ARF and E2F1.  This raises the question of 
how E2F3a-induced apoptosis can be independent of p53 but dependent on several 
upstream regulators of p53.  Previous studies have suggested several factors that may be 
responsible for ATM, ARF or E2F1 to bypass p53 to induce apoptosis.  Among them, the 
p53 related protein p73 has been shown to promote apoptosis in response to several 
stresses (Gong et al., 1999; Jost et al., 1997; Stiewe and Putzer, 2000; Yuan et al., 1999).  
To examine the role of p73 in E2F3a-induced apoptosis, p73-/- mouse embryo fibroblasts 
(a kind gift from Dr. Elsa Flores at UT M.D.Anderson Cancer Center) were infected with 
E2F3a expressing adenovirus or a control virus.  As with the absence of p53, the absence 
of p73 also did not affect apoptosis induced by E2F3a overexpression (Figure 27A).  
Consistent with this finding, the absence of the p73 regulating kinase c-Abl is also 
dispensable for E2F3a-induced apoptosis (Figure 27B). However, in MEFs deficient for 
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both p53 and p73 (a kind gift from Dr. Elsa Flores at UT M.D. Anderson Cancer Center), 
apoptosis in response to E2F3a was much decreased (Figure 27A).  This indicates that 
p53 and p73 may compensate for each other in promoting E2F3a-induced apoptosis. 
 
4.3 DISCUSSION 
           The induction of apoptosis is crucial for elimination of cells with deregulated 
proliferation and serves as an important barrier for tumorigenesis.  In the E2F family, 
E2F1 has been extensively studied for its role in apoptosis and has been considered to be 
the specific E2F member that induces apoptosis (DeGregori et al., 1997; Kowalik et al., 
1998; Lissy et al., 2000).  There’s evidence that in primary mouse fibroblast culture 
systems, ectopic expression of E2F3 induces apoptosis (Lazzerini Denchi and Helin, 
2005).  Along with others, we show in an in vivo system that E2F3a overexpression 
induces apoptosis (Lazzerini Denchi and Helin, 2005; Paulson et al., 2006). Our finding 
in human fibroblast cultures further demonstrates that ectopic expression of E2F3a 
induces apoptosis in a primary human system.  
While E2F3a induces apoptosis in vitro and in vivo, the mechanism by which 
E2F3a induces apoptosis is largely unknown. In the classical pathway of E2F-induced 
apoptosis, deregulated E2F transcriptional activity upregulates ARF expression.  ARF 
inhibits the function of Mdm2, which leads to p53 stabilization and accumulation.  
Upregulated p53 in turn transcribes proapoptotic mitochondria proteins and induces 
apoptosis. An earlier study suggested that E2F3-induced apoptosis is E2F1 dependent 










cell cultures, we show that overexpression of E2F3a upregulates E2F1 expression and 
that the loss of E2F1 impairs the ability of E2F3a to induce apoptosis.   While E2F3a 
mediated apoptosis requires E2F1, there’s also E2F1-independent pathways by which 
E2F3a promotes apoptosis.  Several studies have shown that ARF is dispensable in E2F1-
induced apoptosis, on the contrary, we show that inactivation of Arf reduces E2F3a-
induced apoptosis.  While E2F3a upregulates E2F1 and ARF levels and induces E2F1- 
and ARF-dependent apoptosis, our data show that the loss of E2F1 does not affect the 
upregulation of ARF expression induced by E2F3a.  This suggests that even though E2F1 
is required for E2F3a-induced apoptosis, E2F3a has a distinct apoptotic induction 
pathway from E2F1 that involves ARF but not p53.   
Several studies have shown that overexpression of oncogenic growth factors, 
cyclin E, Cdc25, or E2F1 in cultured cells can activate the ATM signaling pathway 
(Bartkova et al., 2005; Lindstrom and Wiman, 2003; Powers et al., 2004; Vafa et al., 
2002). Consistent with those findings, we find that E2F3a overexpression can also cause 
DNA damage and activate ATM.  Furthermore, when ATM function is lost, it largely 
reduces E2F3a-induced apoptosis. Even though both E2F1 and ARF have been reported 
to activate ATM and promote p53 dependent apoptosis (Li et al., 2004; Pauklin et al., 
2005; Powers et al., 2004), E2F3a-induced ATM activation is not impaired in either Arf  
or E2f1 deficient MEFs.  E2F3a-induced γH2AX foci formation in mouse epidermis is 
also not affected by the loss of E2F1, which suggests that the E2F3a-induced DNA 
damage response pathway is independent of E2F1.  In summary, these data suggest that 
in E2F3a-induced apoptosis, instead of one inter-related pathway with different factors 
regulating each other, there are several parallel pathways. Also note that eliminating a 
key factor does not completely diminish apoptosis induced by E2F3a, but rather only 
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reduces the level of apoptosis. This suggests that the three pathways cooperate and may 
partially compensate for each other’s function (Figure 28). 
One interesting phenomenon we showed here (Paulson et al., 2006) and also been 
shown by another group (Lazzerini Denchi and Helin, 2005) is that deregulated E2F3a 
induces p53-independent apoptosis.  E2F3a-induced apoptosis is partially E2F1 
dependent, and E2F1 induces both p53-dependent and p53-independent apoptosis. In 
E2F1 induced p53-independent apoptosis, the p53 homologue p73 is believed to be 
directly transcriptionally activated by E2F1, leading to activation of p53 responsive genes 
and apoptosis (Irwin et al., 2000; Stiewe and Putzer, 2000).  While it is widely accepted 
that ATM and ARF stabilize p53 and this leads to apoptosis, there are also evidences that 
ATM and ARF also regulate p73 to induce apoptosis (Agami et al., 1999; Gong et al., 
1999; Wang et al., 2001; Yuan et al., 1999).  Using p73 knockout MEFs, we did not see 
apoptosis being affected by loss of p73, but when p53 and p73 were both absent, E2F3a-
induced apoptosis was significantly reduced.  This provides evidence that p53 and p73 
both contribute to E2F3a-induced apoptosis but suggests that p53 and p73 functionally 
compensate for each other in apoptosis induction by deregulated E2F3a.   
Besides p73, all three factors E2F1, ATM and ARF have been shown to regulate 
proapoptotic proteins including Bcl-2 family proteins, Apaf-1 or effector caspases such as 
caspase 3, 7 or 6.  DNA microarray studies show that ectopic expression of E2Fs up-
regulates expression of proapoptotic members of the Bcl-2 family, such as Bok, Bad, Bak 
and Bid1, and effector caspases, including caspase 3 and caspase 7 (Ma et al., 2002; 
Muller et al., 2001).  Induction of E2F1 activity also results in an increase of mRNA and 
protein levels of Apaf1, which activates caspase 9 and consequently caspase 3 and 
caspase 6 (Moroni et al., 2001).  ARF may also induce apoptosis independently of p53 
(Weber et al., 2000), by inducing Bax (Suzuki et al., 2003).  ATM has recently been 
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shown to phosphorylate proapoptotic Bcl-2 family member Bid in response to DNA 
damage, suggesting a possible mechanism for ATM-induced p53-independent apoptosis 
(Kamer et al., 2005; Zinkel et al., 2005).  These proapoptotic factors are potential targets 





















Chapter V Concluding remarks 
5.1 SUMMARY AND DISCUSION OF THE STUDIES 
In this dissertation, I present several novel findings, with one being that we 
provide the first evidence showing that E2F3a, when deregulated, functions as an 
oncogene and contributes to tumorigenesis in a transgenic mouse model.  We also show 
that unlike E2F1, deregulated E2F3a does not suppress, but enhances DMBA/TPA two-
stage skin carcinogenesis.  Second, we demonstrate that the overexpression of E2F3a can 
induce apoptosis in vivo and in vitro, in mouse and human cells.  Thus, in the E2F family, 
E2F3a and E2F1 both have apoptotic induction activity.  Third, E2F3a induces p53-
independent apoptosis and further findings show that the p53 family member p73 and 
p53 compensate for each other’s function in E2F3a induced-apoptosis.  Fourth, E2F3a 
induces DNA damage and this appears to involve increased Cdk activity and aberrant 
DNA replication.  Fifth, the ATM DNA damage pathway is activated in response to 
E2F3a induced-DNA damage and this is important for apoptosis. Finally, we show that 
E2F3a induces apoptosis through unique pathways by activating several parallel 
pathways involving ATM, E2F1 and ARF.  I will expand on these findings in the 
following disccusions. 
            So far, K5 transgenic mouse models for E2F1, E2F3a and E2F4 have now been 
developed in our laboratory (Pierce et al., 1998a; Pierce et al., 1998b; Wang et al., 2000).  
This allows a comparison of the in vivo activities of these E2F family members in the 
same model system with the caveat that the level of exogenous E2F proteins may not be 
exactly the same (Table 2). Each of the E2F family members tested induces 
hyperproliferation and  hyperplasia in the epidermis of transgenic mice.  E2F3a and E2F1 
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also induce increased levels of apoptosis while E2F4 lacks an apoptosis induction 
activity.  However, the mechanism by which E2F3a and E2F1 induce apoptosis appears 
to be different since p53 inactivation reduces apoptosis in K5 E2F1 transgenic mice but 
not in K5 E2F3a transgenic mice.  This agrees with findings from Denchi and Helin 
demonstrating that apoptosis induced by transgenic expression of E2F3 in the pituitary 
gland is also independent of p53 (Lazzerini Denchi and Helin, 2005).  Paradoxically, our 
further findings show that E2F3a-induced apoptosis is dependent on E2F1.  The loss of 
E2F1 significantly impairs the increased levels of apoptosis induced by E2F3a 
overexpression.  We speculate that E2F3a, while it does not require p53 to induce 
apoptosis, does require other proapoptotic activities of E2F1.   Another unique property 
of E2F3a-induced apoptosis is that ARF is required but not p53.  This indicates that ARF 
has other activities that are independent of p53.   
In the effort of finding the mechanistic pathway of E2F3a-induced p53-
independent apoptosis, we tested the role of the p53 family member p73. As one of the 
factors that are important in p53-independent apoptosis induced by E2F1, p73 is a 
downstream target of E2F1 and the activation of p73 has been shown to provide a means 
for E2F1 to induce cell death in the absence of p53 (Irwin et al., 2000). Furthermore, the 
disruption of p73 function inhibits E2F1-induced apoptosis in p53 null cells (Lissy et al., 
2000). ARF also regulates p73 through inhibition of Mdm2 and results in upregulation of 
p73 and its transcriptional activity (Wang et al., 2001).  It was found that like p53, p73 is 
also induced by DNA damage in a c-Abl-dependent manner (Agami et al., 1999; Gong et 
al., 1999; Yuan et al., 1999).  This induction of p73 is mediated through the interaction 
between the SH3 domain of c-Abl and the C-terminal homo-oligomerization domain of 
p73, and the phosphorylation of p73 on Tyrosine 99 by c-Abl. Consistent with the result 
that  loss  of c-Abl does  not  affect  E2F3a-induced apoptosis, in p73 deficient MEFs, the  
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increase in   E2F3a-induced  apoptosis  is  unaffected   compared  to   wild   type   MEFs 
overexpressing E2F3a.  However, in MEFs deficient for both p53 and p73, we see a 
significant decrease in E2F3a-induced apoptosis compared to wild type MEFs.  This 
leads us to conclude that either p53 or p73 is dispensable in E2F3a-induced apoptosis but 
that they compensate for each other’s function when one of them is absent and the loss of 
both p53 and p73 largely impairs E2F3a-induced apoptosis.  To further address the 
regulation of p73 by E2F3a, we have shown that the upregulation of p73 transcription by 
E2F3a is not significant.  Post-translational phosphorylation of p73 could provide another 
mechanism by which E2F3a regulates p73. 
Together with earlier findings that E2F3a is a strong regulator of cell 
proliferation, the finding that deregulated E2F3a induces hyperproliferation and tumor 
development in the K5 E2F3a transgenic model confirmed the oncogenic property of the 
E2f3a gene.  Recent studies have indicated the existence of tumorigenesis barriers that 
involve oncogene-induced DNA damage, which leads to activation of the ATM DNA 
damage response pathway and thereby to apoptosis or senescence (Bartkova et al., 2005; 
Bartkova et al., 2006; Di Micco et al., 2006; Gorgoulis et al., 2005).  In this study, we 
show that deregulated E2F3a expression results in the accumulation of DNA damage, 
most likely double-strand breaks.  This was shown by γH2AX foci formation, a DSB 
damage marker, in both K5 E2F3a transgenic mouse epidermis and normal human 
fibroblasts infected with a recombinant adenovirus expressing E2F3a.  In a more direct 
approach, we used the comet assay to show that deregulated E2F3a induces DNA damage 
in both the K5 E2F3a transgenic keratinocytes and normal human fibroblasts.  In 
response to E2F3a-induced DNA damage, the checkpoint kinase ATM is activated, 
shown by increased autophosphorylation at serine 1981, a well-established marker of 
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ATM activation and DSB.  This activation of ATM contributes to apoptosis induced by 
E2F3a.  In K5 E2F3a transgenic mice, inactivation of Atm significantly reduces the level 
of apoptosis compared to K5 E2F3a transgenic mice with wild type Atm.  To explore the 
mechanism of E2F3a-induced DNA damage, we show using the comet assay that the 
DNA replication inhibitior aphidicolin largely reduces DNA damage caused by 
deregulated E2F3a.  Furthermore, in all eukaryotes, Cdks drive the major cell cycle 
events of DNA replication and mitosis (Forsburg and Nurse, 1991; Reed, 1992). We 
show in this study that the Cdk inhibitor p21, when ectopically expressed in human cells, 
significantly reduces E2F3a-induced DNA damage. At the same time, co-expression of 
p21 also reduces the activation of ATM and the level of apoptosis induced by deregulated 
E2F3a.  These results provide a possible mechanism for E2F3a induced DNA damage 
response, which can be summarized as aberrant DNA replication promoted by 
deregulated E2F3a causes DNA damage.  In response to this DNA damage, ATM 
signaling pathway is activated and results in the cell fate of apoptosis.  
We also show that E2F3a induces apoptosis through unique pathways.  E2F3a 
upregulates another E2F family member E2F1, and the absence of E2F1 reduces E2F3a-
induced apoptosis.  This indicates that E2F3a induces apoptosis partially through E2F1.  
Even though E2F3a induced-apoptosis is partially dependent on E2F1, it also uses a 
different pathway than E2F1 in apoptosis.  In this pathway, E2F3a upregulates ARF and 
induces ARF-dependent but p53-independent apoptosis. We further show that the 
upregulation of ARF by E2F3a is independent of E2F1.  Meanwhile, to examine how the 
E2F1 and ARF-dependent pathways relate to the ATM pathway, we found that the loss of 
either ARF or E2F1 does not affect the activation of ATM by E2F3a.  Therefore, instead 
of a linear pathway, deregulated E2F3a activates several parallel pathways that result in 
the cell fate of apoptosis.   
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5.2 FUTURE DIRECTIONS 
In this study we have convincingly shown that deregulated E2F3a induces p53-
independent apoptosis through several parallel pathways and provided evidence that p73 
may play a role in E2F3a-induced apoptosis. There are several proapoptotic factors that 
are potential targets for E2F3a-induced p53-independent apoptosis that could be 
addressed in future studies in order to understand the mechanism of E2F3a-indcued 
apoptosis even better.  Besides p73, proapoptotic Bcl-2 family proteins, Apaf-1 and 
effector caspases such as caspase 3, 7 and 6 have been shown to be regulated by E2F1, 
ATM and/or ARF. DNA microarray studies show that ectopic expression of E2Fs up-
regulates expression of proapoptotic members of the Bcl-2 family, such as Bok, Bad, Bak 
and Bid1, and effector caspases, including caspase 3 and caspase 7 (Ma et al., 2002; 
Muller et al., 2001).  Induction of E2F1 activity also results in an increase of mRNA and 
protein levels of Apaf1, which when induced, activate caspase 9 and consequently 
caspase 3 and caspase 6 (Moroni et al., 2001).  ARF can also induce apoptosis 
independently of p53 (Weber et al., 2000) through Bax (Suzuki et al., 2003).  ATM has 
recently been shown to phosphorylate the proapoptotic Bcl-2 family member Bid in 
response to DNA damage, suggesting a possible mechanism for ATM-induced, p53-
independent apoptosis (Kamer et al., 2005; Zinkel et al., 2005).  
While E2F3a functions as an oncogene, when deregulated it induces tumor 
development, the tumors develop late in life and less than half of the mice develop a 
tumor.  One possible explanation for this could be that E2F3a-induced apoptosis 
functions as a barrier for tumor development.  Further experiments to characterize the 
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E2F3a apoptotic pathways and examine the role of E2F3a-induced apoptosis in tumor 
development will help us understand more fully the role of E2F3a in tumorigenesis. 
Another interesting finding made during these studies is that E2F3a activates the 
ATM DNA damage response pathway.  Recently, publications by Bartkova et al, Di 
Micco et al and Mallette et al have proposed that the DNA damage signaling pathway is a 
critical mediator of oncogene-induced senescence (Bartkova et al., 2006; Di Micco et al., 
2006; Mallette et al., 2007). Characterization of the role of E2F3a in senescence could 
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